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ABSTRACT

Studies on Encephalomyocarditis Virus-Induced
Diabetes in Mice

by

John H. Huffman, Doctor of Philosophy
Utah State University, 1988

Major Professor: Dr. Reed P. Warren
Department: Biology
The D-variant of encephalomyocarditis (EMC-D) virus was given to
SJUJ mice by the artificial , intraperitoneal (ip) route of infection , or by th e
natural routes of infection per os (po) or intranasal (i.n .), in comparable
concentrations. The po route of infection was found to be ineffective. Mice
given virus by either the ip or i.n . routes of infection became diabetic. Mice
were more resistant to the infectious and diabetogenic properties of the virus
when given by the i.n . than when given by the ip route. Glycosuria in mice
given virus i.n . usually lagged one day behind that in mice given virus ip.
Measurement of glucose in mouse urine by use of Diastix® reagent
strips was found to be a reliable indicator of diabetes . This test was easily and
quickly accomplished without harm or pain to the mice.
Crude virus preparations were compared to purified virus preparations
for their diabetogenic and infectious properties in mice .

No statistically

significant differences in either parameter were observed. Virus prepared by a
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single passage in BHK-21 cells was fully diabetogenic , contrary to a
previously published report.
Male SJUJ mice were infected with a diabetogenic dose of EMC-D
virus by the i.n. route. Relative times of development of virus infection and
mouse resistance parameters were compared to the time of development of
signs of diabetes in the mice. A rapid decrease of plasma interferon titer
corresponded to the time of development of signs of diabetes in the infected
mice. Whether this was coincidental or has some significance in development
of diabetes is unknown.
Tissue sections from pancreas, spleen , kidney, liver, lung , heart, and
thymus were studied by immunohistochemical staining techniques for the
presence of virus antigen, insulin , and the three types of mouse interferon (a,

p, andy).
Glucose was excreted in the saliva of mice with glycosuria. Previous
reports of this excretion in diabetic mice have not been found in the literature.
Mice without glycosuria did not excrete measurable (by Clinistix® or Diastix®)
glucose in saliva.
Some mice were able to control the polyuria, polydipsia, and
polyphagia normally seen in diabetes mellitus.

These mice eventually

reverted from having signs of diabetes to a normal state of plasma glucose
and urine devoid of glucose. The mechanisms by which the mice were able to
do this are unknown at this time.
(133 pages)

CHAPTER I
INTRODUCTION
The disease known as diabetes is actually a collection of many different
disorders, all of which cause excessive excretion of urine . The definition of
diabetes given in Webster's Ninth New Collegiate Dictionary (1, p. 349) is
[L, fr. Gk diabetes , lit., siphon , fr. diabainein] (15c)
: any of various abnormal conditions characterized
by the secretion and excretion of excessive
amounts of urine ; esp : DIABETES MELLITUS
Taber (2, p. D-20) provides 10 terms to explain the different entities known
collectively as diabetes. The definition of diabetes mellitus, or true diabetes,
follows.
A disorder of carbohydrate metabolism
characterized by hyperglycemia, and glycosuria,
resulting from inadequate production or utilization
of insulin.
Diabetes mellitus is further characterized into two general subcategories,
depending on the patient's requirement for externally administered insulin to
control hyperglycemia.

These categories are juvenile-onset (type-1, or

insulin-dependent) diabetes and adult-onset (type-2, or noninsulindependent) diabetes. This investigation is limited to a study of the juvenileonset category of diabetes mellitus using an animal model.
Although diabetes mellitus is known to involve inadequate production
or utilization of insulin, the initiation of the inadequacies of insulin activity is not
well-understood. In 1927, Gunderson (3) proposed that viral infection could
initiate the onset of diabetes. Although no virus had been identified as a
causative agent of diabetes , he made the observation that an increased
frequency of diabetes closely followed epidemics of mumps in children. More
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recently, Craighead (4) reviewed findings which support viral infections as one
possible cause of juvenile-onset diabetes. Mumps outbreaks have often been
noted in close association to development of symptoms of diabetes. However,
there is a lack of documented lesions in the islets of Langerhans in the few
autopsy reports on individuals dying early in the course of infection with
mumps virus . Other viruses common to childhood epidemic disease have
also been implicated in juvenile-onset diabetes by close association in time
with onset and/or by increased prevalence and higher titers of virus-specific
antibodies. Relevant viruses known to cause pancreatitis in man include, in
addition to mumps virus, rubella virus, coxsackievirus group B type 4, and
cytomegalovirus (4).
To effectively study virus as a possible cause of diabetes mellitus, it is
necessary to use an animal/virus model system. There are animal models for
the study of vi rally induced diabetes that employ lymphocytic choriomeningitis
virus (LCMV) (5), Venezuelan encephalitis virus (6), rubella virus (7),
coxsackievirus 84 (8), foot-and-mouth disease virus (9), reovirus (1 0), and
encephalomyocarditis (EMC) virus (11 ). Each is characterized by particular
advantages and disadvantages. Thus,

a model system was chosen that

would best answer the questions posed by the study prospectus.
The mouse model using EMC virus was chosen for this study because
EMC virus is a murine enterovirus (12), and is natural to the model host. It has
also been isolated from stools of human beings and from several other genera
of vertebrates, presumably occuring there as the result of natural infection
(12) . In addition, Yoon et al. (13) found neutralizing antibody titers to EMC
virus in 12% of the juvenile diabetics they studied in contrast to only 6% of
their control subjects. This virus/mouse model is also the most widely studied
of such models.
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It is obvious from the studies involving the EMC virus/mouse model that
either the infectious virus particle itself or something in the cells in which the
virus grows is one of the determining factors in whether or not the viral
preparation will cause diabetes. In all previous studies, it was assumed that
the virus particle itself was responsible for the clinical signs of diabetes. None
of the investigators speculated that the extraneous material (from the cell
culture in which the virus was propagated) had any bearing on the
diabetogenicity of the virus preparation . The infecting virus particles have yet
to be purified from the cell milieu in which the virus inoculum was grown ,
despite the fact that Giron et al. (1 4) found extreme differences in the
diabetogenicity of EMC virus after single passages in different cell lines. Thus,
it is important to determine if purified virus retains diabetogenic properties.
Interferon (IFN) has been implicated (1 4, 15, 16, 17, 18) in the
mechanism of induction of the diabetic state when mice are infected with EMC
virus. Since there have been only superficial investigations into the roll of IFN,
more thorough investigations should be made into the type of IFN which is
produced at specific times relative to diabetogenic infections by EMC virus.
Results should then be compared to the type of IFN that is produced at similar
times in non-diabetogenic infections by EMC virus. In addition, knowing which
tissues are involved in the production of the IFN at those specific times could
be enlightening .
Host factors such as immune competence (1 9, 20) are certainly
involved in diabetogenicity following EMC virus infection ; however, there are
no investigations of the status of the cellular- or the humoral-immune system
components during such diabetogenic infections.
All reported studies of EMC virus-induced diabetes have employed an
artificial means, intraperitoneal (ip) injection, for introduction of the virus into
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the host. However, a more relevant study of virus-induced diabetes might be
possible if the virus were introduced by a natural route of infection.
The objectives of this study are 1) to determine if a natural route of
infection can be reliably used to induce diabetes in mice and if so, to use that
route of infection to continue with the other objectives of the study; 2) to
determine if the virus particle is intrinsically diabetogenic or if it must be
introduced along with supposedly extraneous materials present in the virus
preparation; 3) to characterize host-defense activities in relationship to the
EMC virus infection and development of diabetes; 4) to substantiate findings
by others and ex1end the description of the characteristics of the EMC-D
virus/mouse model of diabetes ; and 5) to use reagent strips used for urinalysis
in humans (Ciinistix® and Diastix®) to determine their reliability as an
indicator of diabetes in mice.
This study is important as a means to elucidate mechanisms involved in
virus-induced diabetes in mice. If these mechanisms could be determined in
animals , it would then be possible to intelligently design experiments to
combat virally induced diabetes in humans.
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CHAPTER II
REVIEW OF THE LITERATURE

Diabetes

Mellitus. Definition .

There are many definitions of

diabetes , depending on the writer and the time that the definition was written .
In Webster's New Collegiate Dictionarv , copyright 1961 (21 , p. 228) , the
definition is as follows :

di'a·be"tes ... A disease attended with a persistent, excessive
discharge of urine ; specif., di"a·be "tes mef.li"tus .. . , or sugar
diabetes, a grave form in which the body is unable to utilize
properly the carbohydrates in the diet due to failure in the
secretion of insulin by the pancreas. It is marked by sugar in the
urine, excessive thirst and hunger, and progressive emaciation .
Currently, definitions by investigators more closely approximate that of
Berhanu and Olefsky (22, p. 265) :
Diabetes mellitus is a complex disorder characterized by
alterations in carbohydrate , lipid , and protein metabolism
resulting from a deficiency of insulin or its cellular metabolic
effects. As a function of time, these metabolic derangements
lead to the development of chronic degenerative changes in the
eyes, kidneys, nerves, and blood vessels, and often result in the
well-known chronic clinical complications of diabetes including
blindness, renal failure , peripheral and autonomic neuropathy,
and occlusive peripheral vascular and coronary artery disease.
Although diabetes mellitus has been recognized for several
centuries, our concepts regarding its etiology and pathogenesis
continue to undergo major changes.
The vivid description of the disease made by Aretaeus could almost
serve as a definition and since it makes so many valid points regarding the
disease, it is quoted here (23, flyleaf) .
Diabetes is a wonderful affection , not very frequent among men ,
being a melting down of the flesh and limbs into urine. Its cause
is of a cold and humid nature , as in dropsy. The course is the
common one, namely, the kidneys and bladder; for the patients
never stop making water, but the flow is incessant, as if from the

6

opening of aqueducts. The nature of the disease , then , is
chronic, and it takes a long period to form; but the patient is
short-lived, if the constitution of the disease be completely
established ; for the melting is rapid , the death speedy.
Moreover, life is disgusting and painful ; thirst unquenchable ;
excessive drinking , which , however, is disproportionate to the
large quantity of urine, for more urine is passed ; and one cannot
stop them either from drinking or making water. Or if for a time
they abstain from drinking , their mouths become parched and
their bodies dry, the viscera seem as if scorched up ; they are
affected with nausea, restlessness, and a burning thirst ; and at
no distant term they expire.
Hence , the disease appears to me to have got the name
'diabetes' as if from the Greek word 8taP1l1:1l<Y (which signifies a
siphon), because the fluid does not remain in the body, but uses
the man's body as a ladder (8uxPa9pJ1) , whereby to leave it.
They stand out for a certain time, but not very long, for they pass
urine with pain, and the emaciation is dreadful; nor does any
great portion of flesh pass out along with the urine.
The cause of it may be , that some of the acute diseases may
have terminated in this : and during the crisis the diseases may
have left some malignity lurking in the part. It is not improbable ,
also, that something pernicious, derived from the other diseases
which attack the bladder and kidneys , may sometimes prove the
cause of this affection.
Aretaeus the Cappadocian, A.D. 81-138
History. A disease, now termed diabetes, was described in the Ebers
Papyrus in 1500 B.C .

However, diabetes seems to be a "disease of

civilization" since its prevalence increases as urbanization , working patterns,
and diet change from primitive to civilized modes (24) .
The name diabetes was applied to the disease by Aretaeus the
Cappadocian , A.D. 81-138 (23, 24). The Greek word for honey, mellitus, was
added when a sweet substance was noted in the urine of patients with
diabetes (24). Butterfield (25) provided a succinct history of developments in
the study of diabetes. He related (25, p. 78) that in 1798 Rollo (26) described
diabetes as "a morbid condition of the stomach forming or developing from
vegetable substances, saccharine matter which is quickly separated as a
foreign body by the kidneys."

It was not until 1851 that Bouchardat (27)
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attributed diabetes mellitus to disease of the pancreas, although he wrongfully
ascribed it to a failure of the external secretion of the pancreas. Von Maring
and Minkowski (28) found that pancreatectomy in dogs caused permanent
diabetes of a severe nature . They also reported that ligation of the duct led to
atrophy of the pancreas but did not cause diabetes. They recognized that the
pancreas has a function that is essential for the utilization of sugar by the
organism.

They evidently did not connect the cells (now called islets of

Langerhans) previously reported by Langerhans (29) with their newly
discovered function of the pancreas. Laguesse (30), however, suggested that
the islets of Langerhans produce a hormone and Schafer (31) related that
hormone to carbohydrate metabolism. It was not until 1921 that Banting and
Best (32 , 33) extracted insulin from the pancreas of dogs and demonstrated its
hypoglycemic activity. Sanger (34, 35) determined the structure of insulin in
the mid-1950s.
According to Berhanu and Olefsky (22) it was thought, immediately
following the reports of discovery of this pancreatic extract by Banting and Best
(32, 33) , that all diabetes mellitus resulted from insulin deficiency. Himsworth
(36) was one of the first to recognize that diabetes is a heterogeneous
disorder when he pointed out that diabetes could be diffe rentiated into
"insulin-sensitive" and "insulin-insensitive" types on the basis of blood-glucose
response to insulin administered after an oral glucose load .

He later

suggested that insulin insensitivity, not insulin deficiency, is present in many
diabetics who are nonketotic and of middle age. This view was strengthened
when Yalow and Berson (37) reported a method (insulin rad ioimmunoassay)
by which endogenous insulin could be measured in the plasma, and it was
found that on the average higher levels of insulin occur in patients with the

r
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adult-onset form of the disease than in normal controls.
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Epidemiology. The National Diabetes Data Group (NDDG) reported in

1985 (38) that approximately 5.8 million people in the U.S. had been
diagnosed as being diabetic and an additional 4-5 million with diabetes
remained undiagnosed. They reported 4 main types of diabetes 1) insulindependent diabetes mellitus (lOOM) , which comprises 5-10% of all cases of
diabetes in the U.S.; 2) noninsulin-dependent diabetes mellitus (NIDDM) ,
which comprises most of the remaining cases; 3) gestational diabetes (GDM),
which is a transient condition during pregnancy , occurring in 2-5% of all
pregnancies; and 4) a type of diabetes that is secondary to or associated with
the other conditions and makes up about 2% of the cases. In addition to these
4 types of diabetes, impaired glucose tolerance (IGT) affects those persons
with glucose tolerance between normal and diabetic (38).
Approximately 500,000 persons each year are diagnosed as diabetic.
The annual incidence is 12-14/100,000 children ages 0-16 years; by age 20 ,
0.3% of persons in the U.S. have lOOM. Two and thirty-five hundredths
percent of the population of the U.S. is diagnosed as having NIDDM , and
those 65 years and older with N lOOM make up 8.6% of the population (38).
Insulin-dependent diabetes mellitus tends to run in families but does
not have a clear genetic etiology or a consistent mode of inheritance (39). The
incidence of lOOM is similar in males and females and is 1.5 times higher in
whites than in blacks, but incidence rates vary widely internationally.
Individuals with particular human leucocyte antigen (HLA) types, especially
DR3 and DR4, are at increased risk for development of lOOM. Additional risk
factors may be advanced maternal age and the presence of islet cell
antibodies. Siblings of diabetic children have a 7 to 18 times greater risk of
developing lOOM than children of the general population . However, only
about 1 child in 50 who is a brother or sister of an lOOM patient will develop
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lOOM. lOOM is one of the major chronic diseases of children , having a risk
similar to that of developing cancer in childhood but having a much greater
risk than other well-known diseases (cystic fibrosis , leukemia, rheumatoid
arthritis , muscular dystrophy, and Hodgkin's disease) (38).
Only limited data concerning the prevalence of lOOM in the U.S. are
available but results obtained are consistent. One child in 600 of school age
has lOOM. Very little is known concerning the prevalence of lOOM in adults
(38) .
Diabetes was the seventh leading underlying cause of death in the U.S.
in 1982, leading to 34,583 deaths . An additional 95,000 deaths were listed
with diabetes as a contributing cause (38) . Mortality among white male and
female lOOM patients was 5 to 11 times greater than in nondiabetics and the
rates for blacks with lOOM were about two times higher than those for whites.
Below age 20 , the primary cause of death in lOOM was acute diabetic
complications, but at older ages renal disease accounted for nearly half of the
deaths. The frequency of renal disease deaths was 500 times higher and of
cardiovascular disease deaths was 13 times higher in lOOM patients than in
the general population (38) .
Diagnosis. A number of prospective observational studies (40, 41 , 42,

43, 44) have led to the tentative conclusion that the pathologic consequences
of diabetes are most likely to occur when blood glucose levels are excessive
over extended periods of time. Consequently, the World Health Organization
(WHO) and the NDDG have recommended criteria for the diagnosis of
diabetes based on plasma glucose levels which are believed to be predictive
of the complications of diabetes. The NDDG and WHO do not consider
diagnostic criteria that employ urine glucose or casual and postprandial
glucose values to be adequate for the diagnosis of diabetes (38) . They
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recommend that diagnosis in a clinical setting be made by one of the
following: 1) the presence of the classic symptoms of diabetes {polyuria,
po lydipsia, ketonuria, and rapid weight loss) together with gross and
unequivocal elevation of plasma glucose, e.g., postprandial or random plasma
glucose concentration> 200 mg/dl (11 .1 mmoi/L) ; 2) elevated fasting glucose
concentration on more than one occasion as follows : venous plasma
mg/dl (7.8 mmoi/L), venous whole blood
whole blood

~120

~ 120

~140

mg/dl (6.7 mmoi/L). or capillary

mg/dl (6.7 mmoi/L) ; or 3) when the fasting glucose

concentration is less than that which is diagnostic of diabetes (see no. 2
above) , an abnormal oral glucose tolerance test must meet the following
criteria: venous plasma

~200

mg/dl (11 .1 mmoi/L), or venous whole blood

180 mg/dl (1 0.0 mmoi/L) , or capillary whole blood

~200

~

mg/dl (11 .1 mmoi/L).

To meet these latter criteria, the NDDG requires both a 2-hour sample and
some other sample taken between administration of the 75-gram glucose
dose and the 2-hour sample, while the WHO requires only a 2-hour sample.
Interpretation of the results of a single glucose tolerance test should be
done with care because there have been reports of a lack of reproducibility of
this testing in normal subjects and in diabetic patients (45). McDonald et al.
(45) found that the degree of carbohydrate intolerance can fluctuate in
diabetics from a normal test at one time to marked intolerance in the same
patient at another time. There have been occasional reports of total remission
of severe diabetes (46, 47, 48) , some of which may have been based on nonreproducible glucose tolerance tests.
Complications of diabetes. Diabetes is the leading cause of new cases

of blindness in people of ages 20-74 years in the U.S.

Oth er common

complications are acidosis and coma, kidney disease , peripheral vascular
disease , heart disease, hypertension , and cerebrovascular disease. It has
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been reported that infections occur more often in diabetics than in
nondiabetics but "many published inferences about infectious consequences
of diabetes go beyond what available data permit. " (49, p. XIX-1) . Most types
of infections are no more common in diabetics than in nondiabetics. However,
kidney and urinary-tract infections do appear at a relatively high rate in
diabetics ; and diabetes is a pre-existing condition in a significant proportion of
patients with certain fungal infections , as well as in some unusual clinical
entities such as invasive eX1ernal otitis (38).
Economic aspects of diabetes. It is difficult to estimate the full economic

impact of diabetes because it is so closely related to other acute and chronic
conditions that may also be the reason for medical expenses.

The lowest

estimates of costs directly attributable to diabetes in the U.S. are $13.8 billion
annually, 3.6% of total health costs. Medical care expenses specifically for
diabetes account for $7.4 billion, while $6.3 billion is due to indirect costs due
to disability and premature death among diabetics.

All costs incurred by

diabetics for medical care are estimated to be about 2-times the above (38) .
Animal Models of Virus-Induced Diabetes Mellitus.

Several

animal models for the study of virus-induced diabetes mellitus have been
described. Some of these models have not been well-developed and have
not received attention by many investigators.

Such models include

lymphocytic choriomeningitis virus in mice (5), foot-and-mouth disease virus in
cattle (9), rubella virus in rabbits (7), reovirus in infant mice (1 0). and a model
described by Rayfield et al. (6) of Venezuelan equine encephalitis virus in
hamsters.
Another model

of virus-associated diabetes mellitus is the

coxsackievirus (CV) type B infection in mice (8) . This model is especially
interesting in light of the fact that some investigators (50 , 51) found
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correlations between antibodies to CV type 84 and the onset of insulin dependent diabetes in humans. They also found a seasonal incidence of
insulin-dependent diabetes mellitus with significant positive correlation with
the annual prevalence data for this virus, but not for other types of viral
infection . Other workers (52, 53, 54, 55, 56) have not been able to confirm
those findings. Interestingly, however, Yoon et al. (57) isolated CV type 84
from the postmortem pancreas of a boy who had been admitted to a hospital in
diabetic ketoacidosis. The boy was admitted within three days of onset of
symptoms of a flu-like illness. The isolated virus caused diabetic signs when
injected into mice. Serum samples from the boy had a titer of neutralizing
antibody to the virus of less than 4 on the second hospital day and 32 on the
8th hospital day, the day of his death . This is the best evidence to date that a
virus is involved in the initiation of diabetes in man.
Some workers have not been able to obtain hyperglycemic glucose
levels in mice injected with CV (58 , 59) . Yoon et al. (60) found that repeated
passage of CV type 84 in mouse pancreatic beta cells led to the isolation of a
diabetogenic variant of this virus, which could then be used to induce diabetes
signs in several inbred strains of mice. In this and another study (61) they
found that repeated passage of CV or EMC virus in secondary mouse embryo
cells did not increase diabetogenic capabilities.
The EMC virus/mouse model for juvenile-onset diabetes mellitus has
been the most studied animal model for diabetes . Although a great deal has
been published regarding this model system there are many questions to be
answered before results obtained from the model can be properly interpreted.
Some of these questions will be addressed in the remainder of this chapter.
Effects of Virus Strain on EMC Virus-Caused Diabetes. The
virus strain is important in determining whether or not an infection will result in
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the diabetic syndrome.

The first report regarding the diabetogenic nature of

EMC virus (11) specified that the diabetogenic activity is seen only in a variant
selected by harvesting the virus from repeated passages in the myocardium of
infected mice.

Craighead and Mclane (11) named it the M variant (from

myocardium) . Many other investigators have since used the M variant to
successfully induce diabetes in various mouse strains ; however, some mouse
strains have consistently been resistant to the diabetogenic effects of the virus.
Yoon et al. (15) demonstrated that the stock of M variant EMC virus is
composed of at least two separate strains, one a diabetogenic variant and the
other a nondiabetogenic variant.

The variants were separated by plaque

purification . The range of ability of the different isolates to cause diabetes was
found to be continuous between 100% and 0%. This could mean that there
were many variants in the original virus stock, each with a different degree of
ability to cause diabetes. Alternatively, it could mean that each plaque isolate
is either a pure isolate of a single variant (either diabetogenic or
nondiabetogenic) or a particular mix of the two variants which gives the range
of variation seen. Two plaque isolates were selected, one of which gave 0%
diabetes when injected into mice (the B variant) and one which induced
diabetes in 100% of the injected mice (the D variant) . When the B and D
variants were mixed together at B:D ratios of 1, 9, and 99 and injected into
susceptible mice, diabetes developed in 60%, 11%, and 0% of the mice,
respectively (15). The investigators expressed confidence in the stability of
the properties of these two variants since, unlike the M variant stock, repeated
passage in secondary mouse embryo cells did not cause the D variant to lose
the capacity to produce diabetes in mice.
It now seems evident that the diabetogenic nature of the D variant
depends upon the type of cells in which it is grown. Giron et al. (14) found that
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the D variant continues to be diabetogenic when grown in L-929 (L) cells , a
mouse-derived line, while a single passage of the virus in baby hamster
kidney (BHK-21) cells completely eliminates the diabetogenic ability of the
virus.

The diabetogenic ability of the D variant is fully restored by a single

passage in a human cancer cell line (He La), but not by a single passage in L
cells. Therefore, Giron et al. (14) suggested that the D variant, like the M
variant from which it was isolated , either consists of more than one distinct
virus or is relatively unstable and some of its properties are easily altered
during replication in certain cell types.
Recently Kruppenbacher et al. (62) reported that they were able to take
the EMC-D variant supplied by Yoon and isolate a non-diabetogenic variant
by further plaque purification . The D variant could have been in a continual
mutation mode away from the diabetogenic variant, or the D variant as
isolated by Yoon and his colleagues could have been an impure virus stock.
Physical and chemical differences of EMC virus variants. The only

differences noted so far between EMC-D and EMC-8 virus variants are 1)
their diabetogenic abilities (15, 63), 2) their relative ability to induce production
of interferon (IFN) in cell culture or in mice (although both variants are equally
sensitive to inhibition by IFN) (15), 3) the plaque size in L cells (64), and 4) at
least one oligonucleotide in the fingerprinting pattern of the T1-digested RNAs
from the two variants (65, 63). Hybridization and thermal elution profiles of the
RNAs from the two variants failed to demonstrate any differences, but the
fingerprint of the T1-digested RNA of the B variant was missing at least one
oligonucleotide , 20 to 25 nucleotides long, which was present in the digest of
the O-varian! RNA. Four of the structural proteins (alpha, beta, gamma, and
delta) of the two variants migrate identically on SDS-PAGE , with a pattern
I•

II
1:

similar to that already known for EMC virus capsid proteins. No differences in
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the sensitivity to different pH values, salt concentrations, ultraviolet irradiation
or temperature, as measured by infectivity of the viruses , could be found (65).

Host

Regulated

Factors

Involved

in

Resistance

or

Susceptibility to EMC Virus-Induced Diabetes Mellitus. Effect of
genetics. The resistance of certain mouse strains to induction of diabetes by

infection with EMC virus was early proposed to be due to the genetic traits of
the resistant mice (66) . The inherited trait for resistance was said by Yoon
and Notkins (67) to be due to resistance of the beta cells of the pancreas to
both infection by, and production of, EMC virus. They found that the beta cells
isolated from resistant strains of mice and grown in vitro had lower infection
percentages and produced a less infectious virus than did the beta cells from
sensitive strains of mice.

In contrast, EMC virus replicated equally well in

primary embryo or kidney cell cultures from susceptible or resistant strains of
mice . They concluded that the development of EMC virus-induced diabetes is
related to genetically determined host differences which affect the ability of the
virus to infect beta cells. The same group of investigators (68) demonstrated
that EMC virus selectively binds in vitro to the beta cells derived from a
susceptible strain of mice as compared to the beta cells from a resistant strain
of mice. They concluded that genetically inherited viral receptors cause the
differences seen in susceptibility among mouse strains.
Ross et al. (69) and Yoon et al. (70) had shown in earlier studies that
when mice were infected with EMC-M virus, some strains of mice were
susceptible and other strains were resistant to EMC virus-induced diabetes.
When susceptible mice were crossed with resistant mice, the F1 progeny
were resistant to the diabetogenic effects of the virus. However, more than
20% of the F2 offspring developed diabetes when infected by the virus. The
backcross of the F1 progeny to the resistant parents gave offspring which were
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also resistant.

In contrast, when the F1 progeny were backcrossed to the

susceptible parents, approximately one-half of the offspring were susceptible
(71 ). The authors concluded that these data are consistent with theories of
Mendelian inheritance, and that susceptibility to EMC virus-induced diabetes
is controlled by a single locus.
Dafoe et al. (72) performed an experiment in which male F1 hybrids
from a cross between resistant and susceptible strains of mice were induced
to diabetes signs by chemical means. The diabetic hybrids then received
pancreatic transplants from neonates of either the resistant or the susceptible
parental strains of mice . Encephalomyocarditis virus was injected into these
mice, into sex- and age-matched untreated F1 hybrids, and into each parental
strain . The parental strains were either susceptible or resistant to the
diabetogenic effects of EMC infection, as expected. The untreated F1 hybrids
were intermediate in susceptibility, while the F1 hybrids with transplants were
also intermediate in susceptibility , regardless of source of the pancreatic
transplant. These results indicate that host factors are more important than are
inherited pancreatic factors in determining susceptibility to EMC-induced
diabetes.

Effect of hormones and age. Testosterone is one host factor which
appears to be important in the determination of mouse susceptibility to virusinduced diabetes. Morrow et al. (73) found that intact male DBA/2 mice (sham
operated) and male castrates treated with testosterone and infected with the M
variant of EMC virus had pancreatic insulin concentrations that dropped
precipitously to 10% of control values with concomitant hyperglycemia.
Untreated castrates failed to develop hyperglycemia, although the insulin
content of the pancreas dropped somewhat in these infected animals. Equal
amounts of viral antigen were demonstrated in beta cells of untreated
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castrates and those of the other mice .
Testosterone is not a determining factor in diabetogenic susceptibility in
all strains of mice, according to Giron and Patterson (74). They found that
testosterone-treated ICR Swiss female mice, normally resistant to EMC virusinduced diabetes, were just as susceptible to diabetes induction as male mice
when infected with the D variant of EMC virus. In contrast, testosteronetreated DBA/2J female mice were not susceptible to the virus. Other steroid
hormones (estrone, cortisone , and progesterone) were not effective in
increasing the susceptibility of ICR Swiss female mice to EMC virus
diabetogenicity.
Giron et al. (75) have also found that age of the recipient mice largely
determines their susceptibility to the diabetogenic effects of EMC-D virus. ICR
Swiss mice younger than 7 weeks developed lethal encephalitis when
infected with the D variant of EMC virus, while those older than 7 weeks
developed diabetes. Testosterone injections enhanced the susceptibility of
the young mice to the diabetogenic effects of the virus . On the other hand ,
testosterone had no effect on the susceptibility of 9-week-old mice to EMC-D
virus. It is not clear at this time why the EMC-0 virus loses the ability to infect
the central nervous system of older mice.
Effect of interferon. Yoon et al. (15) speculated that differences in IFN

stimulating ability of the two EMC virus variants could account for the
difference in diabetogenic potential. The B variant stimulates normal levels of
IFN while the D variant stimulates little or no IFN production either in cell
culture or in mice. On the other hand, Giron et al. (14) found that the ability of
the virus to induce interferon in cell culture had no bearing on whether or not
the virus pool would retain its diabetogenic characteristics . Recently, Yoon et
al. (16) repeated their claim that the IFN system is an important determinant in

18

the outcome of EMC virus-induced diabetes in mice.

They reported that

repeated administration of IFN or an IFN inducer reduced EMC-D virusinduced diabetes in mice, while a single treatment with either IFN or its
inducer had no effect. They also found that treating mice with antibody to
murine IFN allowed development of mild signs of diabetes in those mice
injected with the B variant of EMC virus.
The host strain of mouse influences whether or not IFN, or a variety of
IFN inducers , inhibit the diabetogenic effect of EMC-D virus. The diabetogenic
effect of EMC-D vi rus in SWR/J mice was blocked by either 13-IFN or a variety
of IFN inducers, but the effect was not blocked in ICR Swiss mice by the same
treatments (17) . The authors implied that in ICR Swiss mice, 13-IFN and the
IFN produced in response to the inducers poly I:C, pyran , endotoxin , or
tilorone either do not reach the beta cells of the pancreas, or the beta cells are
not sensitive to the protective action of IFN. The same group of investigators
(18) found that when 13-(actually a mix of 13- and a-) or y-IFN was
administered to adult male ICR Swiss mice four days after infection with EMCD virus, the frequency and severity of diabetes signs were increased.

In

addition , the diabetic state was induced in the resistant C57BU6 strain of mice
under the same conditions. The IFN preparations were given after the acute
stage of infection, but prior to the onset of insulitis (mononuclear cellular
infiltration of pancreatic islets) . They concluded that under certain conditions,
the diabetic state is exacerbated and the normal course of EMC-D virus
infection in mice is altered by IFN.

Effect of immune system capabilities. The cellular immune system of
mice must be functional in order for EMC virus to cause diabetes in infected
animals. However, the humoral immune system functionality seems to be of
little consequence (20). Buschard et al. (19) found that the EMC-M strain of
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virus was unable to induce diabetes in athymic (nu/nu) mice , but heterozygous
littermates (+/nu) and normal mice of the background strain C57BI/6
developed diabetes mellitus.
Immunosuppression of DBA/2 mice with the cyclophosphamide
derivative Asta 5122 significantly increased the mean value of blood glucose
levels compared to the positive controls, even though the percentage of
diabetic animals (88%) was the same in both groups. In contrast, X-irradiation
(500 R) caused a significant inhibition of the appearance of diabetes in the
EMC-M virus infected mice.

Neither chemical immunosuppression without

viral infection nor X-irradiation alone caused diabetes in the mice .

The

irradiated mice infected with virus did not have insulitis , but the chemically
treated mice with virus had a high incidence of insulitis (20).
In the study of Buschard et al. (19), EMC virus was isolated from all
inoculated animals.

They concluded , "it is the response of the thymus-

dependent lymphocyte system evoked by the virus rather than the virus itself
that leads to damage to the insulin producing cell" (19, p. 299). The same
group (76) extended their investigations and found that the M strain of EMC
virus also did not cause diabetes in athymic nude mice of BALB/c origin. In
contrast, 36% of normal mice developed diabetes when infected with EMC-D
virus and 93% of the infected normal mice, but none of the nude mice ,
developed paresis of one or more legs. Virus could be isolated in abundant
amounts from the pancreas and heart of all virus-inoculated mice, including
the non-diabetic nude mice. Although the thymus-dependent immune system
seemed important in this model , the primary mechanism for affecting the islet
beta cells was not a massive lymphocytic infiltration in the islets.
Virus replication in various tissues. Gould et al. (64) reported

differences in the replication of the D and B variants of EMC virus in organs of
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male ICR Swiss mice. The D variant replicated in the spleen, pancreas, heart,
lung , and intestines of the mice but EMC-B virus replication was limited to the
spleen and pancreas. The EMC-B virus strain interfered with the replication of
EMC-D virus in each of the tissues examined.

Insulin levels were initially

increased by both viruses, but by 4 days postinfection, insulin levels were
either normal or undetectable in the EMC-D virus-infected mice and were
dramatically elevated in those mice infected with the B variant.

The

concentration of the D variant was much greater in the spleen than in the
pancreas of mice with normal glucose tolerance test (GTT) results but the
relative concentrations of virus were reversed in the 2 tissues of mice with
abnormal GTT results. The D variant replicated, but to a very limited extent, in
the heart, lung, and intestinal tissues.

Even though the B variant did not

replicate in these tissues, it still managed to block the multiplication of EMC-D
virus.

ICR Swiss mice were not protected against EMC-D virus-induced

diabetes by IFN injections; therefore, IFN activity was not the mechanism of
protection when EMC-B virus was used in these mice.

Immunohistochemical Techniques . lmmunoperoxidase staining.
The enzyme horseradish peroxidase (HAP), of molecular weight 40,000, is
employed in the immunoperoxidase technique as a marker for identification of
antibodies or antigens at both the cellular and subcellular levels. interaction
of horseradish peroxidase with certain substrates produces insoluble reaction
products that can be demonstrated by both light and electron microscopy (77).
Avrameas and Uriel (78) and Nakane and Pierce (79) were pioneer
investigators of this method. They proposed independently that enzymes be
used in the place of fluorochromes as labels for antibodies.
Disadvantages of immunofluorescence that immunoperoxidase
staining overcomes include quick fading of fluorescence preparations, the
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requirement of photography to provide permanent results, limited resolution of
the fluorescence microscope, nonadaptability of fluorescence to electron
microscopy, inability to use counterstains, and the inability to use paraffin- or
resin-embedded sections to perform retrospective studies on stored blocks
from past years.
Disadvantages of immunoperoxidase staining include 1) the
demonstration of relatively minute positively staining areas is limited by the
light microscope's resolution , 2) endogenous peroxidase, which causes
nonspecific staining, may not be completely eliminated from the tissue under
investigation, and 3) products resulting from the enzyme reaction may diffuse
away from the area where antigen is localized (77).
Mukai and Rosai (80) applied immunoperoxidase techniques to
histochemical staining for diagnosis in surgical pathology. This technique has
greatly improved the diagnostic capabilities of the surgical pathologist.
Peroxidase-antiperoxidase

technique.

Sternberger et al. (81)

developed a peroxidase-antiperoxidase (PAP) method that allowed use of
unlabeled antibody, thus overcoming a disadvantage of the original
peroxidase-labeled primary antibody technique in which it was necessary to
label each antibody specificity and individually. The same PAP complex may
be used for many different unlabeled antibody specificities.
Avidin-biotin-peroxidase complex technique.

The avidin-biotin-

peroxidase complex (ABC) technique, introduced by Hsu et al. (82, 83), is a
major advance .

This method allows use of highly diluted antibody

preparations previously only used in radioimmunoassay techniques.

The

ABC procedure employs primary antibody without label, secondary antibody
labeled with biotin, a low molecular weight (244 daltons) vitamin, and a
preformed avidin-biotinylated horseradish peroxidase complex. Avidin (from
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egg white) is a glycoprotein of molecular weight 68 ,000 . It has an extremely
high affinity (Kd=1 o·15 M-1) for biotin which leads to an essentially irreversible
union , in contrast to reversible antigen-antibody reactions. To stain by this
method , the tissue section is incubated with a primary antibody specific for the
antigen in question and then biotinylated secondary antibody is applied. This
is followed by exposure to the ABC complex which binds very tightly to the
biotin of the secondary antibody. Visualization is accomplished by incubation
in a solution of peroxidase substrate to form an insoluble pigment at the site of
the peroxidase enzyme. Avidin has 4 separate binding sites for biotin . When
it is incubated, in excess, with biotin-peroxidase molecules, a large lattice-like
complex develops which is still capable of binding to other biotin molecules.
The structure of the complex is unknown , but is believed to consist of
numerous biotinylated horseradish peroxidase molecules cross-linked by
avidin to give a three-dimensional structure (84) .
The ABC staining method is capable of providing multiple molecules of
the peroxidase enzyme at the site of antigen-antibody reaction, in contrast to
the PAP method in which an average of only 2.4 molecules of peroxidase can
be attached to each molecule of tissue antigen (77). Hsu et al. (82 , 83) found
their ABC method to be 8-40 times more sensitive than the PAP technique.
This method is also more universal than the PAP technique in that it eliminates
the necessity of preparing peroxidase-anti-peroxidase complexes in different
species. There is also no need for excess linking antibody, as in the PAP
method, because biotin coupled to the secondary antibody serves as the link
and only a minimum amount is necessary because of the high affinity of the
biotin-avidin reaction (77).
Many biological molecules, including enzymes and antibodies, can be
biotinylated without significant loss of biological activity (85) .
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Unlike directly conjugated enzyme-labelled second antibodies,
biotinylated second antibody is, essentially, identical in size to the
immunoglobulin molecule and is therefore able to penetrate tissue
sections much more readily than its more bulky counterpart . This
property can prove important in strongly fixed sections and it
reduces the need for protease treatment of sections. (85, p. 34)
Likewise avidin can be conjugated with a wide variety of labels without
inactivation of activity. Thus, the biotin-avidin system provides a great promise
of numerous potential applications. However, there are two major problems
that arise because of the chemical structure and properties of avidin derived
from egg-white. 1) Avidin is highly positively charged at neutral pH because
of its isoelectric point, which is approximately ten (86). Staining done at a pH
near neutrality leads to nonspecific binding of the avidin to negatively charged
molecules (87) such as nucleic acids or phospholipids, resulting in high
background labeling.

2)

Avidin is a glycoprotein and will thus react with

biological molecules such as lectins through its carbohydrate moiety (88) .
Streptavidin, a protein of molecular weight 60,000, isolated from
Streptomyces avidinii (89), has four high-affinity (Kd=1 o-15 M-1) binding sites

and may be conjugated with a variety of label molecules in a manner that
retains activity. The properties of streptavidin are very similar to those of
avidin .

However, in contrast to egg-white avidin, streptavidin has an

isoelectric point near neutral pH, contains no carbohydrate moieties, and has
a molecular weight that is 8000 daltons less than avidin (85) . In contrast to
avidin, streptavidin exhibits little non-specific binding to mast cells, kidney,
liver, or brain tissue at physiological pH (89, 90).
Controls. It is absolutely essential that proper controls be included with

each staining procedure (77). There are two necessary controls : 1) A positive
control slide which is fixed and embedded in an identical manner to the test
slides and which is known to contain the antigen in question. This slide is
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necessary to determine that the reagents are performing properly.

2) A

negative control slide, with the same characteristics as the positive control
slide, is essential to show nonspecific staining reactions .

This slide has

primary antibody omitted and nonimmune serum substituted during the
staining procedure. This control slide permits examination for endogenous
peroxidase activity as well as nonspecific binding of secondary antibody.

Substrates.

One of the earliest substrates utilized in immune-

peroxidase staining was 3,5'-diaminobenzidine (DAB). The enzyme produces
an insoluble brown pigment when DAB is the substrate .

There is a

modification of the DAB peroxidase staining to produce a jet blue-black
pigment [personal communication of Hsu in (77)] .

These pigments are

insoluble in water as well as in organic dehydrating and mounting media.
Thus, when DAB is used, the slides can be permanently mounted and referred
to over long periods of time since the pigment also does not fade . This
substrate has the disadvantage of being a potential carcinogen (77).

A

substrate utilized to avoid the carcinogenic potential of DAB as well as to
provide a contrasting staining color is 3-amino-9-ethyl-carbazole (AEC) . It
provides a red to brownish-red reaction product which is soluble in organic
solvents. Thus, aqueous mounting media must be used to mount tissue
sections when this substrate is used. Some AEC sections fade during storage
over a period of several months (91, 92).
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CHAPTER Ill
A NATURAL ROUTE OF INFECTION STUDIED
IN THE MOUSE MODEL OF DIABETES
INDUCED BY EMC VIRUS

Introduction .

Previously published studies on the induction of

diabetes by EMC virus in mice have used an artificial route, intraperitoneal (ip)
injection, of the virus. While this means of introducing the virus is certainly
effective in producing diabetic signs in the mice, it may yield results which are
somewhat different than those obtained following a natural route of infection.
This study was carried out in order to determine if a natural route of
infection, either per os (po) or intranasal (i.n.), by EMC virus would reliably
produce diabetes in mice. The i.n. route was effective in establishing diabetes
in mice. It allowed a comparison of diabetic signs obtained following infection
by the i.n. route to those seen after ip injection of the virus.

Materials and Methods. Mice. Male and female adult mice of the
SJUJ strain, a highly inbred strain of white mouse, obtained from The Jackson
Laboratory (Bar Harbor, ME) were used to begin a small breeding colony in
our laboratory. This strain of mice was used by Yoon et al. (15) to demonstrate
different strains of EMC in a stock of M variant EMC virus.

Mice of various

ages were used to determine if there is a relationship between mouse age
and the diabetogenic potential of the virus. The mice were housed in shoe
box style cages, fed Wayne Lab Blox and given tap water ad libitum. Ground
corn cobs were used as bedding .

Cells. L-cells, a continuous culture of mouse connective tissue cells,
were obtained from the American Type Culture Collection (ATCC). Rockville,
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Maryland, as NCTC clone 929 cells and were maintained in growth medium
which was different from the original med ium in wh ich they had been
developed. For this reason, they are no longer considered to be the NCTC
clone 929 cells and are thus called L-cells. See the following quote from the
ATCC Catalogue of Strains II, Fourth Ed., 1983, page 17 (93) , regarding the
description of this clone of cells. "If the cells are maintained in the original
medium , they may be considered NCTC clone 929 cells; if grown in other
media, they may exhibit different properties and should be considered to be
derivatives or sublines" (93, p.17). The continuous culture of BHK-21 , Syrian
hamster, Mesocricetus auratus, kidney cells, was purchased from ATCC.
Medium. Eagle's Minimum Essential Medium (EMEM) with Earle's salts

and non-essential amino acids (GIBCO, Grand Island, NY) , containing 5%
fetal bovine serum (FBS) (Hyclone Laboratories, Logan, UT), 0.1% NaHC03,
and without antibiotics was used as growth medium for L-cells. The growth
medium for BHK-21 cells differed only in that the concentration of FBS was
increased to 9%. EMEM containing 2% FBS , 0.18% NaHC0 3 , and 50 llg of
gentamicin/ml was used as diluent when virus or other material was being
titered and is referred to as test medium in this study.
Virus. Two different EMC-D virus preparations, one labeled "EMC-D, 4-

29-82, 100% diabetes" and the other labeled "EMC-D, P-3, 7/80", were kindly
provided by Dr. J. Yoon of the National Institutes of Health . The one dated 429-82 will be referred to as the '82 virus pool and the other preparation will be
referred to as the '80 virus pool. The '82 virus pool was passaged in L-cells in
our laboratory for use in all other experiments. The cells were infected with
the virus, which was allowed to adsorb for 1 hr, test medium was added, and
the cells were incubated at 37° C. When the viral cytopathogenic effect (CPE)
was graded 4 (100% of the cells showing CPE) the cells, with medium and

27
virus , were frozen at -80°C.

Later, the cells were allowed to thaw at room

temperature, with occasional shaking of the ice sheet over the surface on
which the cells had been growing, in an attempt to suspend all cell material.
The resulting suspension was homogenized for 30 seconds at the full speed
setting of a Sorvall® Omni-Mixer (DuPont Co., Newtown , CT) while the
stainless steel cup was in an ice bath . The homogenate was dispensed to
freezer vials, labeled, and placed at -80°C.
Vesicular stomatitis virus (VSV), Indiana strain (ATCC, Rockville, MD),
was passaged in MA 104 cells in a manner similar to that described for EMC-D
virus.
Titration of virus in vitro. Two methods, cell culture infectious dose-50%

endpoint (CCIDso) and plaque assay, were used in these experiments for in
vitro virus titrations. These titrations were accomplished in the same cells (Lor

BHK-21) utilized to conduct other assays in which the virus was used as a
challenge .
The CCIDso endpoint was determined by titration in cells grown in 96well, flat-bottomed, tissue culture plates (A/S Nunc, Denmark or Corning Glass
Works, Corning, NY) (96-well microplates) .

Cells suspended in growth

medium were seeded in these sterile plates at 2 x 1os cells/ml, 0.2 ml/well.
The plates were wrapped in Saran WrapTM (The Dow Chemical Co.,
Indianapolis, IN) and incubated overnight at 37°C to allow the cells to form
confluent monolayers.

Virus was diluted by serial 10-fold dilutions in

polystyrene, 12 x 75 mm, sterile, snap-cap tubes (Becton Dickenson and Co. ,
Lincoln Park, NJ or EIKay Products , Inc., Shrewsbury, MA) containing test
medium as diluent. The growth medium was decanted from the plates and the
diluted virus was placed in specified wells within the plate (0.1 ml/well, 4
replicate wells/dilution). The plate was wrapped with fresh Saran WrapTM and
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returned to the 37°C incubator. The CPE resulting from virus growth within the
cells was graded by microscopic examination after 3 days of incubation. The
50% endpoint of the titration was determined by the method of Reed and

Muench (94), considering wells with any degree of CPE within the contained
cells to be infected, and those wells lacking CPE within the cells to be
uninfected.
For plaque assay of virus, L-cells or BHK-21 cells were seeded in 6well tissue culture plates (NS Nunc, Denmark) at 2 x 1os cells/mi. 3 ml /dish.
The dishes were placed at 3?0C in a humidified atmosphere of 5% C0 2 , 95%
air, and the cells were allowed to grow to confluence (2-3 days). The growth
medium was aspirated from the cells and 0.1 ml of a specified virus dilution (in
test medium) was placed in the center of the cell sheet in each of 2 wells. The
virus was allowed to adsorb for one hour at 3?0C with rocking every 15
minutes to keep the cells moist. The cells were then overlaid with 3 ml of a
mixture of equal volumes of doubly concentrated test medium and 2% Sea
Plaque® agarose (FMC Corp., Marine Colloids Div., Rockland, ME) prepared
in glass distilled water. The medium and agarose were tempered to 37°C
before mixing. The agarose was allowed to solidify at room temperature and
the dishes were placed at 37°C. When CPE was evident in the cell sheets (12 days), 1 ml of sterile neutral red in normal saline (one part in 5000 parts)
was placed in each dish and allowed to penetrate the agarose at 37°C for a
minimum of 2 hours. The excess neutral red was aspirated and the dishes
returned to the incubator in the dark. The plaques could usually be counted 34 hours later.
Mouse interferon activity in L-ee/Is and in BHK-21 cells. Interferon (IFN)

production was induced in L-cells by exposing 7-day old cell sheets, in tissue
culture flasks, to a miX1ure of 0. 1 mg/ml DEAE Dextran (Pharmacia, Uppsala,
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Sweden) and 0.01 mg/ml polyinosinic-polycytidylic acid , sodium salt (poly I:C)
(Sigma Chemical Co., St. Louis, MO) in test medium lacking serum.

The

mixture was left on the cells at 37°C for 1 hr and then decanted. The cell
sheets were rinsed 2 times with modified Puck's balanced salt solution . Test
medium supplemented with 0.2% Primatone® RL, a peptic digest of animal
tissue (Humko Sheffield Chem ., Memphis, TN), was added to the flasks . The
cells were incubated in this medium at 3?0C for 42 hr to allow production of
IFN. Medium was collected from the flasks of L-cells, centrifuged to remove
cells and cell debris, dispensed to vials, and frozen at

-aooc for future assay.

The IFN activity of this preparation was titered by diluting it in test
medium and assaying it in both L-cells and BHK-21 cells. The assay was
carried out by placing ten-fold dilutions of the IFN (from undiluted to 1o-6) on
18-hour monolayers of cells in 96-well microplates from which the medium
had been decanted. Each dilution of IFN was placed in 4 replicate wells of the
plate at 0.1 ml/well. The IFN dilutions (or diluent medium without IFN) were
incubated on the cells at 37°C for 42 hr before they were decanted from the
cells, and 0.1 ml of challenge virus was added to each well. Both VSV and
EMC-D virus, each diluted to the same concentration of 100 CCIDso/0.1 ml,
were used as challenge virus to titer this IFN preparation in the two cell lines.
When the virus control cells (those exposed to medium lacking IFN) were
100% destroyed by the virus, all of the wells in each plate were examined
microscopically and graded for the ex1ent of development of viral CPE. The
dilution of sample which provided a 50% endpoint of viral CPE was calculated
and the inverse of this endpoint was defined as the IFN titer (units/0.1 ml) of
the sample (95).

Tests on mouse urine. Clinistix®, Diastix®, and Bili-Labstix® Reagent
Strips for Urinalysis (Ames Division, Miles Laboratories, Elkhart, IN) were used
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for analysis of urine samples. Both Clinistix® and Diastix® are plastic strips
with single reagent areas designed to react with glucose. The reagent area of
each type of strip contains 2 enzymes, glucose oxidase, which catalyzes the
formation of gluconic acid and hydrogen peroxide from the oxidation of
glucose, and peroxidase, which catalyzes the reaction of hydrogen peroxide
with a chromogen . The Clinistix® reagent area contains the chromogen
orthotolidine, with which hydrogen peroxide produces colors ranging from
purple through blue. A potassium iodide chromogen in the Diastix® reagent
area is oxidized by hydrogen peroxide and peroxidase, to colors rang ing from
green to brown, according to the concentration of peroxide present.

Bili-

Labstix® Reagent Strips are plastic strips with 6 separate reagent areas fixed
to the strip. One of the reagent areas is the same as the Diastix® reagent area
and is used to quantitate glucose in the urine. The other reagent areas are
individually designed to detect blood, bilirubin , ketone, protein, and the pH of
the urine. Detailed instructions provided with each of these products were
followed carefully in the testing procedure.
Preparation of mouse plasma samples. Pasteur pipets and 1 ml

polystyrene centrifuge tubes (Allied Fisher Scientific, Pittsburgh, PA) were
heparinized by dissolving 4 g of sodium fluoride (Sigma chemical Co., St.
Louis, MO) in 100 ml of water to which 0.5 g (-170 units/mg) of heparin,
sodium salt, (Sigma) was added and allowed to dissolve.

The heparin-

sodium fluoride solution was drawn into and expelled from the Pasteur pipets
which were then dried in an incubator.

One drop of the heparin-sodium

fluoride solution was added to each centrifuge tube and the tubes were dried
in an incubator before use.
Selected mice were individually anesthetized with ether, the brachial
artery clipped, and the blood collected in a heparinized Pasteur pipet and
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transferred to a heparinized centrifuge tube. These samples were centrifuged.
Plasma was collected from each sample , placed in a labeled freezer vial , and
stored (-80°C) for future tests.
Determination of plasma glucose levels. Glucose concentration was
determined by an enzymatic colorimetric method proposed by Kaston (96) and
modified by Raabe and Terkildsen (97) . The method is based on the coupled
enzymatic reactions of glucose oxidase and peroxidase , as in the urine test
strips ; however, in this case, the chromogen is o-dianisidine . Oxidized odianisidine is brown and this color intensity , measured at 425-475 nm, is
proportional to the glucose concentration in the sample tested. The procedure
outlined in Sigma Technical Bulletin #510, provided with the kit, was modified
as to volumes of sample , enzyme mixture, and color reagent solution to
facilitate utilization of small amounts of sample in a 96-well flat-bottomed
tissue culture plate. The results were measured at 450 nm in a microplate
reader (Bio-Tek Instruments, Winooski , VT).
Titration of neutralizing antibodies in plasma. Each plasma sample was
diluted in test medium by preparing a single 10-fold dilution (on occasion a
20- or 50-fold dilution was made if the sample volume was insufficient for a 10fold dilution) . This dilution tube was heated at 56°C for 30 minutes and then
serial 2-fold dilutions were made from the initial dilution . Equal volumes (0.5
ml) of each diluted plasma sample and a virus preparation containing 100
CCIDso of EMC-0 virus/0.1 ml, were mixed together and incubated at 37°C for
1 hr in a water bath. Virus control mixtures (0.5 ml of diluent , without mouse
plasma, and 0.5 ml of the virus preparation) were similarly incubated . Onetenth ml aliquots of each mixture were placed in each of 3 wells of a 96-well
microplate containing confluent monolayers of BHK-21 cells. Diluent medium
(0 .1 ml) without virus or mouse plasma, was placed in each well designated
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as cell control wells. The cells were incubated at 37°C until all virus control
wells had a CPE grade of 4 and the cell control wells were all still in very good
condition (CPE grade of 0). The neutralizing antibody titer of each serum
preparation was determined by calculating the 50% endpoint by the method of
Reed and Muench (94). Wells with any degree of CPE were considered to be
unprotected and those without CPE were considered to be totally protected by
the antibodies in the plasma.
Mouse experiments in which infection was by the ip route.

The '82

virus pool was diluted in test medium to obtain approximately 1 x 1as pfu/0.1
mi. The '80 virus pool was used undiluted to obtain the approximate same
concentration of virus. Neither of these viral preparations had been passaged
in our laboratory prior to use in this experiment. Seven mice received an ip
injection of 0.1 ml of the '82 virus preparation, 7 mice received an equal
volume of the '80 virus preparation, and 7 mice received 0.1 ml of diluent
without virus by the same route. Twelve male and 9 female mice were used in
the initial experiment.

Clinistix® test strips were used each day to test all

urine samples for glucose spillage (glycosuria) . Glycosuria was first evident
on day 4 post virus inoculation (p.i.), so 3 mice from each group (control and 2
virus preparations) were sacrificed for plasma glucose and antibody
determinations. The remainder of the mice were sacrificed on day 7 p.i. for
like determinations, except that one of the '80 virus-infected mice died on day
7 p.i.
The '82 virus preparation was used to infect L-cells. The virus pool
obtained from this first L-cell passage was assayed by ip injection of mice to
determine if cell passage in our laboratory would diminish the diabetogenic
potential of the virus. All experimental materials and methods were similar to
those used in the first experiment except for the following : 1) the virus pool
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was different, as noted above; 2) concentrations of 10, 1Q2, 1Q3 , 1Q4 , 1as, and
1 as pfu of virus/mouse, given by the ip route , were used to determine the
potency of the virus for diabetogenicity in mice; 3) one mouse from each
group, given different concentrations of virus, was sacrificed on days 4, 7, 14,
and 21 to determine levels of plasma glucose and neutralizing antibody; 4)
several female mice, negative for glycosuria on days 4, 7, and 14, were saved
until day 21 to determine if additional female mice would develop glycosuria
when given a longer time period after the virus infection; and 5) Diastix® test
strips were also used to measure glycosuria on the day of sacrifice if the
mouse was positive by Clinistix® on that day.
Selection of a natural route of infection. The L-cell passaged virus was
introduced to male SJUJ mice by po, and i.n. routes of infection, with the ip
route of infection used as a control. Five mice were selected for each group,
but only 4 mice received virus by the i.n. route because one mouse was killed
by the anesthetic. Five control mice each received 0.1 ml of sterile diluent
medium by the ip route . The ip injections were given by use of a one ml
syringe with a 26 gauge needle attached .

The po inoculations were

administered with a 20G-1.5" perlektum® (Popper and Sons, Inc., New Hyde
Park, NY) intubation needle attached to a one ml syringe.

The i.n. virus

delivery was accomplished by use of a micro-pipetter and micro-pipet tips after
the mice had been lightly anesthetized with ether. The mice exposed to virus
by the i.n. route received 50 J..LI of virus which was 5 x 1Q4 pfu/mouse , instead
of the 1 x 1as pfu/mouse received by mice exposed to virus by the ip and po
routes. On day 6 p.i., all living mice were exsanguinated by clipping the
brachial artery and collecting blood while the mouse was anesthetized.
Plasma samples were collected, labeled, and frozen for later testing . Urine
samples were tested daily for glucose by Clinistix® and by use of Bili-Labstix®
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on the day of sacrifice.
Titration of the diabetogenicity of EMC-0 virus in mice inoculated by the
i.n. route. Male SJUJ mice were inoculated i.n. with virus concentrations

ranging in 10-fold increments from 4 pfu/mouse to 4 x 1as pfu/mouse . The
virus was given in 20 Ill aliquots because in the initial experiment, some of the
mice failed to inhale all of the 50 111 inoculum that was presented. Five mice
were used for each concentration of virus. Five control mice were each given
20 Ill of the sterile virus diluent by the i.n. route. Glycosuria was determined
daily by use of Clinistix® test strips. Diastix® test strips were used daily for
each mouse previously shown to be positive by Clinistix®. On day 7 p.i., all
mice were exsanguinated to obtain plasma samples that were frozen for later
assay.
Statistical analysis.

Statistical analysis on the number of positive

results/total samples was done by chi square analysis. The Student's t-test
was used to analyze significance of means obtained from glucose
measurements.

Results. Activity of mouse IFN in L-ee/Is and BHK-21 cells. The IFN
induced by treatment of L-cells with poly I:C was devoid of protective activity
against either VSV or EMC-D virus in BHK-21 cells, but had good activity
when assayed against either virus in L-cells. Results of the titration are shown
in Table 111-1.
Experiments by the ip infection route.

Parameters used as diabetic

signs in the mice were glycosuria and plasma glucose levels greater than 3
standard deviations above the mean plasma glucose concentration in the
uninfected controls.
Results of Clinistix® testing of the urine of mice injected with EMC-D virus
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TABLE III-I. TITRATION OF MOUSE INTERFERON (IFN)
IN BHK-21 CELLS AND L-CELLS.
Percent of cells with vinJs CPE
~s

IFN

Y..S.Y.. i!l ·

dilution

BHK-21 Cells

Undilute
10-1
10-2
10-3
10-4

100
100
100
100
100

No IFN

100

~s

EMC-Q Y..i(US ill ·

L-cells

BHK-21 cells

L-cells

0

100
100
100
100
100
100

0
0
0
81
100
100

0
0
9
94
100

which had not yet been passed in tissue culture in our laboratory are summarized in Table III-II. These data represent tests on most of the mice at each day
indicated; however, since some mice withheld urine at one or more sample
times, all mice in the experiment were not represented by data at each time
period.
All mice with glycosuria on the day of their sacrifice also had plasma
glucose concentrations greater than 243 mg/1 00 ml, which was 3 standard
deviations above the mean glucose level of the 7 control mice. The mean of
the plasma glucose concentrations of the 4 mice with diabetes that were
sacrificed on day 4 (all males) was 331 mg/1 00 ml, with a range of 273-381
and a S.D. of 46. The 5 mice with diabetes that were sacrificed on day 7 (3
males and 2 females) had a mean plasma glucose concentration of 377
mg/100 ml, with a range of 274-500 and a S.D. of 100.
The 4 female mice which provided a urine sample on day 4 were
negative for glycosuria as were all male and female mice sampled previous to
day 4. Two of 4 female mice tested on day 5 were positive by Clinistix®. They
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TABLE 111-11. GLYCOSURIA IN MICE INJECTED BY THE ip ROUTE
WITH 2 EMC-0 VIRUS POOLSa.
Da~s

Source of sample
0

2

after virus inoculation
3
4
5

6

7

Control mice

Of6b

0/6

0/4

Of6C

0/3

0/3

Of4d

Infected mice

0/12

0/9

0/5

7/12

6/8

6/8

5/7

Infected males

017

0/5

0/3

718

4/4

4/ 4

3/3

Infected females

0/5

0/4

0/2

0/4

2/4

2/ 4

2/4

All receiving '82 virus

017

0/4

0/3

3/6e

3/4

3/4

3/4f

All receiving '80 virus

0/5

0/5

0/2

4/6e

3/4

3/4

2/39

a Both virus pools were provided by Dr. Yoon and had not been passed in
our lab prior to use in this experiment.
b

Number positive/number of samples provided.

c Two males and 1 female were sacrificed.
d

Two males and 2 females were sacrificed.

e Two positive males and 1 negative female were sacrificed.
t Two positive males and 2 females (1 positive) were sacrificed.

9 One positive male and 2 females (1 positive) were sacrificed.
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both remained positive until day 7, when the experiment ended. None of the
other female mice showed signs of diabetes by either parameter, although all
mice injected with virus exhibited evidence of infection by development of
neutralizing antibodies to the virus. The 6 mice which were sacrificed on day
4 had a mean titer of 322 units of neutralizing antibody/0.1 ml of plasma
(range: 200-480; 8.0 .=119). The 7 infected mice which were sacrificed on
day 7 had a mean titer of 1706 units of neutralizing antibody/0.1 ml (range:
480-4470; 8 .0 .=1334). None of the control mice sacrificed on day 4 or day 7
p.i., had detectable antibody (1 0 units/0.1 ml was the lower limit of detection) .
Four male mice infected with virus (3 which rece ived the '80 virus
preparation and 1 infected with the '82 virus pool) developed paralysis of one,
or both, hind legs. Three of these mice were sacrificed on day 4 p.i. , and the
remaining mouse was dead on day 7 p.i.
The '82 EMC-0 virus passed in L-cells also caused diabetes in mice.
All infected male mice became diabetic, even when as little as 10 pfu of the
virus was administered ip to the animals. All males except 1 were positive for
diabetes by Clinistix®, Oiastix®, and plasma glucose. The one exception had
a plasma glucose concentration well within the control range , although both
indicators of glycosuria were positive. The total number of infected mice with
glycosuria varied considerably (Table Jll-111) . All male mice injected with virus
were glycosuric by day 5 and remained so throughout the experiment.

In

contrast, only 9 of 14 females became glycosuric at any time in the
experiment, 1 as late as day 7.

Two of the female mice had cured of

glycosuria before they were sacrificed. Therefore, the variation was due to the
numbers of female mice that developed, or recovered from , glycosuria. All
female mice that developed glycosuria did so by day 7 p.i.
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TABLE 111-111. GLYCOSURIA IN MICE INJECTED BY THE ip ROUTE
WITH VIRUS PASSED IN l - CELLS

Source of sample
0

Number of days after virus inoculation
4
7
21
14

Control mice

014a

0/4

0/3

0/2

ob

Mice infected with 10 pfu

0/4

0/4

2/3

1/2

0/1

Mice infected with 102 pfu

0/4

2/3

3/3

1/2

0/1

Mice infected with 103 pfu

0/4

212

2/2

1/2

0/1

Mice infected with 104 pfu

0/4

2/3

2/3

1/2

0/1

Mice infected with 1os pfu

0/4

3/3

3/3

2/2

1/1

Mice infected with 1os pfu

0/4

2/3

2/3

0/ 1C

0/1

All infected mice

0/24

11 / 18

14/ 17

6/ 11

1/6

Infected male mice

0/ 10

5/6d

717e

3/3f

09

Infected female mice

0/ 14

6/12h

7/10i

3/8C,k

a Number positive/number of samples obtained.
b Mouse died on day 18.
c Mouse died on day 13.
d Two positive male mice sacrificed.
e Five positive male mice sacrificed.
f

Three positive male mice sacrificed.

g All males previously sacrificed.
h

Four females sacrificed (3 positive and 1 negative) .

i One positive female sacrificed.
k Two positive females sacrificed.

m Six females sacrificed (1 positive and 5 negative) .

116m
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Results of Clinisti x® te sting of the urine of the mice did not always agree
with results of plasma glucose testing . Most discrepancies (3 of 4) occurredin
female mice (Table III-IV). Results of tests on mice sacrificed on day 21 were
not included because plasma samples were mistakenly discarded .

Natural routes of infection. In an experiment to determine if a natural
route of infection could be used to obtain diabetic signs in SJUJ male mice ,
two natural routes, i.n. and po , were compared to the commonly used ip route.
As evident in Table 111-V, none of the control mice nor the mice which received
virus by the po route showed signs of diabetes on any of the sample days.
One of the mice given virus by the po route died on day 3 p.i., and one which
received virus by the i.n. route was dead on day 6. One mouse infected by the
ip route (the one with the lowest plasma glucose level) was near death
immediately before sacrifice on day 6. Three of 4 mice infected by the ip route
began showing glycosuria as early as day 4 p.i. and all mice in this group had
developed high glycosuria, as well as diabetic plasma glucose levels, at the
time of sacrifice . The mice infected by the i.n. route began spilling glucose
one day later than those infected ip , with the earliest onset on day 5 p.i.
However, on day 6 p.i. , all of these mice exhibited high levels of plasma and
urine glucose similar to those found in the ip-infected mice. In both situations
(ip and i.n .), the increased positives/total were statistically significant. None of
the control mice, nor those exposed to virus by the po route, developed
neutralizing antibody to the virus. However, all mice exposed to the virus by
either the i.n. or the ip routes developed neutralizing antibody titers greater
than 200 units/0.1 ml by day 6 p.i. The magnitude of the antibody titers, as
related to the concentration of plasma glucose present on the day of sacrifice,
is recorded in Fig . 111-1, along with similar results from other experiments. Little
correlation could be made between concentration of plasma glucose and
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TABLE III-IV. COMPARISON OF 3 PARAMETERS USED TO DETERMINE THE DIABETIC
STATE IN MICE INJECTED BY THE ip ROUTE WITH VIRUS PASSED IN l-CELLS.
Source of sample

Day of sacrifice post-virus inoculation

Cia

Dib

PGC
196*

Female, 10 pfu

o·

o·

Female, 102 pfu

D

5

Female, 103 pfu

D

Cl

Di

PG

Cl

Di

PG

477
188*

Female, 104 pfu

L

o·

Male, 1os pfu

D

5

514

Male, 1os pfu

D

2

392

302

Female, 10 pfu

D

Male, 102 pfu

D

n.s.d 154*
1

186*

Male, 103 pfu

D

5

372

Male, 104 pfu

D

5

562

Male, 1os pfu

D

5

426

Male, 1os pfu

D

5

412

Male , 10 pfu

D

5

611

Female, 102 pfu

L

o·

176*

Male, 103 pfu

D

5

767

Male, 104 pfu

D

5

722

Female, 105 pfu

D

5

385

a Clinistix® results: O=negative; L=light; M=medium; D=dark.
b Diastix® results: O=negative; 1=1 00; 2=250; 3=500; 4=1 000 ; 5=~2000
mg/100 mi.
c Plasma glucose concentration (mg/1 00 ml) .
d No sample obtained.
• Non-diabetic result.
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TABLE 111-V. OIABETOGENICITY OF EMC-0 VIRUS ADMINISTERED BY DIFFERENT
ROUTES IN MALE SJUJ MICE.

Qal£S 8f!er ~irus lnQQijlaliQn
___L. ~ ___..5.._
Virus
Clinistix Clinistix Clinistix
inoculation Pas./
Pas./
Pas./
total
total
total
route

Diastix
Pas./
total

Plasma gi~JQQSe
Pas. a;
Titerb
total

Neutral.
antibody
titer:

None

0/3

0/3

0/4

0/5

0/5

151

0

po

0/3

0/3

0/4

0/4

015

150

0

i.n.

0/4

0/3

2/3

3/3

3/3

452

3840

ip

0/4

3/4

2/3

515

5/5

522

2582

a 2:3 S.D. above the mean plasma glucose cone. of control mice sacrificed
on day 6.
b mg/100 ml (mean) .
c units/0.1 ml (mean).
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FIG . 111·1 . Scatter graph of the relationship between plasma glucose con·
centration and antibody titer in mice inoculated with EMC·D virus.
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antibody titer. The correlation coefficient (R) calculated for the straight line of
best fit to the data points was 0.04. A table of critical values for the Pearson
correlation coefficient was used to test the validity of the hypothesis that a
correlation between concentration of plasma glucose and antibody titers
existed.

The P-value was found to be > 0.05 , indicating no statistical

correlation .
Results of Bili-Labsti x® tests of the urine other than glucose (blood ,
bilirubin , ketone, protein, and pH) were not consistently different between
control and infected mice and were not done in other experiments.

Titration of virus by the i.n. route of infection. Results of tests for
glycosuria and plasma glucose, as well as neutralizing antibody titers of all
mice exposed i.n . to the virus, are summarized in Table Ill-VI. None of the
control mice, nor those which received either 4 or 40 pfu of virus, developed
signs of diabetes or neutralizing antibodies . Only one of five mice which
received 400 pfu of virus was diabetic during the experiment. This mouse
exhibited glycosuria for the first time on day 6, was positive for diabetes by
glycosuria and plasma glucose , and was the only mouse in this group positive
for neutralizing antibody on day 7. Two of 5 mice which received 4 x 103 pfu
of virus were not diabetic by any parameter. However, one of these mice had
a high titer of neutralizing antibody while the other mouse had no neutralizing
antibody. The other 3 mice in this group developed high levels of urine
glucose, plasma glucose , and neutralizing antibody. All of the mice inoculated
with 4 x 104 pfu of virus showed glycosuria at some time during the
experiment.

Two of the mice were negative for glucose in the urine by

Diastix® on the day of sacrifice , although one of these mice earlier (day 5) had
a Diastix® reading of 500 mg/100 mi. This reading dropped to 250 mg/100 ml
on day 6 and was negative on day 7, even though the Clinistix® reading was

TABLE

Ill-VI. TITRATION OF INTRANASALLY ADMINISTERED EMC-0 VIRUS IN MALE SJUJ MICE.
pays after virus inoculation

___a_

____.!__

___.5__

___6__

Clinistix
Pos./
total

Clinistix
Pos./
total

Clinistix
Pos./
total

Clinistix
Pos.
total

4

0/4

0/5

0/4

0/3

4x10

0/5

0/3

0/5

4x102

0/5

0/4

4x103

0/4

4x104
4x105

Virus
cone.
(pfu/mouse)

Diastix
Pos./
total

Elasrna ghiQQS!l
Pos.a/
total

Titerb

Neutralizing
antibody
titer<:

0/5

0/5

168

0

0/3

0/5

0/5

196

0

1/4

1/4

1/5

1/5

249

512

1/4

3/5

1/3

3/5

3/5

373

1278

0/5

1/4

4/5

4/5

3/5

3/5

374

3460

0/5

1/4

5/5

5/5

5/5

5/5

384

1711

a ~3 S.D. above the mean plasma glucose cone. of control mice sacrificed on day 7.
b mg/100 ml (mean).

c units/0.1 ml (mean).

~
~
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medium for glucose on the day of sacrifice . The other Diastix®- negative
mouse had a positive Clinistix® reading (dark) for the first time on the day of
sacrifice. Neither of the two Diastix®-negative mice had high plasma glucose,
but the other 3 mice were diabetic by plasma glucose as well as by Diastix®
on day 7. All of the mice in the group exhibited high neutralizing antibody
titers in the plasma taken on day 7. The earliest times of glycosuria in this
group of mice was day 4 (one mouse) . Three others began spillage on day 5,
and the last mouse showed no glycosuria until day 7. All of the mice in the
group receiving 4 x 1os pfu of virus were diabetic by both parameters tested.
One of these mice began spilling glucose in the urine on day 4, and the other
4 began spilling on day 5. All of these mice also developed neutralizing
antibody specific to the virus.

Discussion. The comparative titration of mouse IFN in L-cells and
BHK-21 cells was carried out in order to identify a cell line which would not
respond to mouse IFN. A cell line of this type was necessary to insure that
neutralizing antibody titrations could be performed without interference by
mouse IFN, which was present in some of the plasma samples to be tested.
BHK-21 cells served this purpose well. They were very sensitive to infection
by EMC-D virus and pretreatment with mouse IFN did not alter this sensitivity.
Thus, the "species specificity" of mouse IFN is valid in this case ; i.e. mouse IFN
is inactive in cells from the hamster (BHK-21 cells).
There was no apparent difference in the diabetogenic potential of the 2
different pools of virus received from Dr. Yoon when studied prior to cellculture passage in our laboratory. However, the '80 virus pool caused a few
more mice to develop central nervous system infections than did the '82 virus
pool. For this reason , the '82 virus pool was chosen as seed for cell culture
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passage in our laboratory to prepare vi rus for additional experiments.
The preparations of EMC-D virus supplied by Dr. Yoon , as well as the
virus pools prepared in our laboratory in L-cells, were diabetogenic in SJU J
mice to the same extent as that previously published by others (14, 15, 18, 62).
In agreement with previous investigators (74), it was found that this virus
induced diabetes in a higher percentage of male mice than it did in female
mice when they were injected with identical amounts of the virus. This was
apparently due to a hormonal effect, according to the work of Morrow, et al.
(73) , Giron and Patterson (74), and Giron, et al. (75). Male mice began spilling
glucose in the urine one day earlier than the female mice, as seen in Table IIIII . In the experiment summarized in Table 111-111, 4 of the male mice were
glycosuric on day 3, while none of the female mice spilled glucose on that day
(data not shown) .

Others have not reported a difference in time of

development of diabetes among male and female mice.
Only four of the published reports (11, 62 , 73, 76) dealing with this
mouse model of diabetes referred to the measurement of glucose spilled in
the urine. These reports only briefly mentioned that the investigators had
tested urine for glucose. No comparisons were made between results of the
urine- and blood-glucose tests.

None of the investigators consistently utilized

this measurement as an indicator of development of diabetes in the mice. It
seemed logical that methods developed for, and widely used by, humans for
demonstration of diabetic symptoms, could also be used to demonstrate
diabetic signs in mice. Since mice tend to urinate as they are being handled,
it was decided to investigate the use of commercially prepared indicators of
glucose in the urine , namely Clinistix® and Diastix® reagent strips.

Bili-

Labsti x® were also used in one experiment to determine if other abnormal
conditions would develop in the urine in the short period of time necessary for
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the virus to cause diabetes in mice. Lack of abnormal results, other than
glycosuria, unique to the diabetic mice, as well as the difficulty of collecting
sufficient urine at the proper time to accomplish all of the tests on each reagent
strip, precluded use of Bili-Labstix® strips in additional experiments.
The experiments presented here demonstrate that normal SJUJ mice
do not spill sufficient glucose in the urine to be detected by reagent strips
designed to detect glycosuria. A total of 93 control mice were tested for
glycosuria on a daily basis over periods of time from 4 days to 64 days, and
none had a positive test. Thus, it was assumed that a positive finding with
either Clinistix® or Diastix® test strips indicated that the tested animal has had
some part(s) of its normal glucose control mechanism altered toward
production of diabetic signs.
In the experiment in which the '80 and '82 EMC-D pools were
examined, all of the mice which spilled glucose in the urine , as determined by
Clinistix ® measurement, also had plasma glucose levels which were
considered to be in the diabetic range. These results suggested that Clinistix®
testing is in complete agreement with the more cumbersome method of
measuring glucose levels in the plasma of the mouse . However, in other
experiments, there were some positive Clinistix® tests of urine from mice
which had plasma glucose concentrations in the normal control range. These
results seem contradictory because one would not expect spillage of glucose
into the urine until after blood glucose levels were above the "renal threshold
concentration" at which tubular reabsorption of glucose no longer matched the
filtered load (98). Certainly, one would have expected spillage of glucose into
the urine once the "threshold concentration" was reached. In cases of such
contradictory results, virus infection may have altered the active transport
mechanism of the renal proximal tubular cells so that glucose was spilled into
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the urine while blood glucose concentration remained within a normal range.
Alternatively, plasma glucose might have increased to a level sufficient to
cause a threshold concentration in the proximal tubule for a period of time,
thus allowing urine in the bladder to contain glucose. However, by the time
the mouse was sacrificed, the plasma glucose level was back to normal, while
the urine stored in the bladder still contained measurable glucose.
Pitts (99) described a clinical condition known as intercapillary
glomerulo-sclerosis in which glycosuria could be absent despite high plasma
glucose concentrations .

This condition is due to a reduced glomerular

filtration rate caused by deposition of a mucopolysaccharide-protein complex
in the glomerular capillary. If the passive glomerular filtration rate is so easily
affected, the more complicated , active transport mechanism of tubular
reabsorption could be inhibited greatly by something as pervasive as viral
infection.
The Diastix® test strips were not as sensitive in these experiments as
the Clinistix® strips , but they are designed to be quantitative. Therefore, a
Diastix® reading would be expected to more closely agree with the results of
plasma glucose measurements. Either an initial threshold level of glucose or
a transient threshold level could allow non-reabsorbed glucose to be diluted
sufficiently in the bladder to give negative, or low, Diastix® readings, even
though Clinistix® tests were positive. Only a glucose imbalance which had
increased over a period of time would be sufficient to give high Diastix®
readings. All test mice had plasma glucose levels greater than 3 S.D. above
the mean plasma glucose level of control mice when the Diastix® reading of
their urine was 250 mg/1 00 ml or above.
Lack of sufficient virus to cause a generalized infection was not the
reason that some of the mice failed to develop diabetic signs.

All mice
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injected with virus by the ip route developed virus-specific antibody in the
plasma, even as early as 4 days after the virus had been injected , and when
only 10 pfu of virus was given to each mouse. Not all of these mice became
diabetic.
Experiments by the i.n. route of infection demonstrated that all mice
which failed to develop neutralizing antibody also failed to show diabetic
signs. One mouse, although given the high dose of 4000 pfu of virus, failed to
develop either circulating antibody or diabetes. Four of the 5 mice given 400
pfu of virus were similarly negative in both categories . Thus, either some
specific site must be infected by the virus , or some specific set of
infection/resistance parameters must be achieved , in order to trigger
development of diabetic signs. During the development of the particular set of
circumstances necessary for triggering diabetic signs, the virus must achieve
an infection that is sufficiently generalized to initiate antibody production .
However, the magnitude of virus neutralizing antibody production has a low
correlation with the concentration of glucose in the plasma, indicating that the
neutralizing antibody alone is not responsible for high glucose levels.
It was clear from the results of these experiments that mice can be in a
transient state of glucose imbalance to the extent that they spill glucose into
the urine for a period of time, and then return to normal conditions. Female
mice appeared bet1er able than male mice to resist and/or overcome the
diabetogenic effect of this virus. However, a few male mice, at least those
exposed to a low to intermediate dosage of the virus, were sometimes also
able to overcome the diabetogenic effect of EMC-D virus. In these cases, the
males also had transient glycosuria, and seemed to return to normal glucose
balance .

The mechanisms by which some individuals were able to

successfully resist the diabetogenicity of this virus is not known. One purpose
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of this study was to provide an improved model to be used in the
determination of these resistance mechanisms.
The i.n. route of infection is an excellent natural route of infection for this
virus/mouse model of diabetes development. When this route of infection is
used, the diabetic signs generally begin to appear a day later than when
infection is by the ip route . However, when a high titer (~1 os pfu) of virus is
used to infect males , the ultimate percentage of mice induced to develop
diabetic signs is essentially the same whether the i.n. or the ip route of
infection is used. On the other hand, the po route of infection was completely
ineffective for induction of diabetic signs in the mice. In fact, the mice were
totally resistant to generalized infection as determined by a complete lack of
development of neutralizing antibody when a high concentration of the virus
(1 os pfu/mouse) was introduced by this route.

It was surprising that the po route of introduction of EMC virus was
ineffective in establishing an infection in the mice. This virus is classified as a
mouse enterovirus and is resistant to low pH , although somewhat conflicting
reports as to the extent of this resistance have been published (12 , 100, 101 ).
Because of its classification as an enterovirus, EMC virus would be expected
to be infectious by the po route. In fact, according to one author (1 02, p.565),
"Occasionally, mice can be infected with virus-contaminated drinking water.",
and, "Contact transmission among cotton rats and infection by feeding in the
case of albino mice have been demonstrated" (1 02, p.567).

Others have

reported that several species of monkeys have been infected by the po route
(12). Craighead et al. (1 03) have infected swine with EMC virus by the oral
route. It is possible that selection of the diabetogenic strain of the virus also
eliminates the virus strain which is resistant to low pH .

However, this

possibility, as well as the possibility that the wild-type virus is not infective by
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the po route of infection, has not been tested.
The diabetogenicity of the virus is more dose responsive when given by
the i.n. route than when given by the ip route . This could be due to the fact that
virus introduced by the artificial route of infection circumvents some of the
mechanisms of natural resistance to infection encountered in the natural route
of infection . This conclusion is supported by study of neutralizing antibody
data obtained following i.n. exposure to different concentrations of EMC-D
virus. All of the mice that received less than 400 pfu of virus were able to
eliminate the virus before it was able to stimulate antibody production, i.e.
before a generalized infection was established .

Four of the 5 mice that

received 400 pfu of virus were able to eliminate the virus prior to
establishment of sufficient infection to induce circulating antibody. Even when
virus was given at a concentration of 4 x 103 pfu/mouse, 1 of the 5 mice
escaped infection sufficient to produce detectable antibodies in the plasma.
Conversely, when virus was given by the ip route , all mice developed
neutralizing antibodies, even when as little as 10 pfu of virus was given.
Titration of the diabetogenicity of the virus in male mice revealed that
low doses of virus, similar to those which caused diabetic signs when given by
the ip route, were ineffective when introduced by the i.n . route. However, with
increasing concentrations of virus, the percentage of diabetic mice increased
to 100%. With the i.n. infection, diabetogenicity is related to the dosage of
virus administered. Thus, adjustments of the virus concentration should allow
one to more fully study the differences in host resistance occurring in mice that
are or are not susceptible to the diabetogenic aspects of the virus. This should
be possible, even if the virus strain and dosage are identical in each case.
Conversely, when the virus causes diabetic signs in 100% of the mice, control
mice for study of resistance factors involved in permitting or prohibiting the
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diabetic state must either be non-infected mice or mice infected by a nondiabetogenic virus.

Thus, the i.n . route of infection by intermediate

concentrations of this virus may enable one to differentiate the quirks in
resistance mechanisms that allow the virus to establish a diabetic condition in
the mouse.

Conclusions. Mouse IFN was not active in BHK-21 cells. Therefore,
the neutralizing antibody titers determined in these cells were not affected by
the presence of IFN in the mouse plasma.
Measurement of glucose in the urine of mice by use of Clinistix® and
Diastix® reagent strips provided a reliable method to determine if the mice
were diabetic or not.

The method was easily and quickly accomplished

without harm or pain to the mice. The only deficiency in the method was that
sometimes individual mice failed to provide a sample of urine for testing .
A natural route of infection, the intranasal route, was found to be
reliable in allowing the EMC-D virus to cause a diabetogenic infection in male
SJUJ mice. The i.n. route of infection, unlike the ip route, provided a wide

range of dose response for the diabetogenicity of EMC-D virus. When mice
were given either 4 or 40 pfu of virus i.n., they remained free of diabetes and
also did not develop neutralizing antibody.

Twenty percent of the mice

developed diabetes when given 4 x 102 pfu of the virus. When 4 x 1Q3 pfu of
virus was given i.n., 60% of the mice developed diabetes.

Half of those

without diabetes at this concentration of virus, also lacked antibody specific for
the virus. All of the male SJUJ mice given ~4 x 104 pfu of EMC-D virus i.n.
developed diabetes. As little as 10 pfu of this vi nus, given to male SJUJ mice
by the ip route, caused 100% of the mice to become diabetic. All mice which
developed diabetes, regardless of the route of infection, also produced
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neutralizing antibody to the virus.
When virus was given by the po route, no signs of infection were
observed .

The mice did not develop diabetes nor did they produce

neutralizing antibody.
Some mice became temporarily diabetic by the EMC-D virus infection
and then spontaneously recovered. The mechanism by which this recovery
occurred is unknown .
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CHAPTER IV
EFFECTS OF PURIFICATION ON THE
DIABETOGENICITY OF
EMC-D VIRUS

Introduction. Craighead and Mclane (11) published the first report of
a strain of encephalomyocarditis (EMC) virus causing diabetic signs in mice.
These investigators named the diabetogenic strain of EMC virus, which they
had isolated from the heart tissue of infected mice, the M-variant ; M standing
for myocardium . More recently, Yoon et al. (15) were able to purify several
strains of EMC virus from the M-variant by plaquing techniques. The purified
strains seemed to differ only by their relative ability to cause diabetes in a
particular strain of mouse. Some of the plaque isolates had no ability to cause
diabetes in the mice, some had the ability to cause 100% of infected mice to
develop diabetes, and other isolates were intermediate in their diabetogenic
ability.
Yoon 's group expressed confidence that their D variant (EMC-D),
diabetogenic in 100% of the male mice infected by it, was stable in this
property, since they had passaged the virus variant repeatedly in secondary
mouse embryo cells without diminishing its diabetogenic ability. However,
Giron et al. (14) suggested that the D variant consists of either more than one
distinct virus strain, or that it is a relatively unstable strain, the properties of
which are easily altered during replication in various cell types. They came to
this conclusion after observing that EMC-D virus displayed different degrees of
diabetogenicity according to the type of cells from which it was harvested.
The altered diabetogenicity observed by Giron et al. could have been
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due to cell material in the crude virus preparations used in the experiments.
Perhaps it is not the virus alone, but a combination of certain materials from
th e cell culture along with the virus, that is responsible for producing the
diabetic state . Alternatively, materials from certain cell cultures may mask the
diabetogenic ability of the virus. At this time, it is only known that certain
strains of EMC virus appear to vary in their ability to cause diabetes in mice
according to the type of cells in which the virus was prepared.
The purpose of this investigation was to determine if purification of
EMC-D virus would alter its diabetogenic characteristics.

Materials and Methods. Virus.

EMC-D virus was prepared by a

single passage in L-cells as outlined in the materials and methods section of
Chapter Ill.

A few small aliquots of the crude virus preparation were

dispensed to vials and frozen for later comparative assays. The remainder of
the virus pool was purified as outlined in the next section.
Virus purification. Sixty-seven ml of ice-cold Freon 113 was added to

250 ml of the homogenized virus pool in a 400 ml stainless steel Sorvall®
Omni-M ixer cup (DuPont Co. , Newtown, CT) , and the mixture was
homogenized for one min at 8,000-10,000 rpm in an ice bath.

The

homogenate was transferred to Nalgene® #3119-0050 polyallomer 50 ml
screw cap tubes (American Scientific Products, Sunnyvale, CA) which had
been sterilized in the autoclave. The tubes were placed in the SS-34 rotor of
the RC-2-8 centrifuge (Ivan Sorvall, Inc., Norwalk, CT) and centrifuged at
2,000 rpm for 10 min. at 0°C.
The clear red supernatant liquid was carefully decanted from each
centrifuge tube and collected in a sterile 1,000 ml Erlenmeyer flask. This
resulting virus pool was mixed and placed in an ice bath . A few 0.2 ml
aliquots of the pool were dispensed to freezer vials and placed at

-sooc

for

56
later assay.
The pH of the Freon extracted pool was 7.8. After adding 3.5 ml of 10%
acetic acid in an ice bath , the pH was 4.8. Very fine , white , hair-like particles
began to appear in the bright yellow liquid after about 5 min.

After

appro ximately 30 min., some of the liquid was poured into 2 sterile Nalgene
polyallomer tubes and these were centrifuged in the SS-34 rotor of the Sorvall
RC-2-B centrifuge at 4,000 rpm for 10 min. at 4°C. The supernatant liquid was
decanted into a sterile tissue culture flask (Corning Glass Works, Corning , NY)
and the above centrifugation step was repeated after more of the acidified
virus preparation was decanted into the tubes .

These two steps were

repeated until all of the virus preparation had been centrifuged. After the final
centrifugation , a small white button could be seen in one of the centrifuge
tubes before the supernatant liquid was decanted. Both centrifuge tubes were
washed with 0.5 ml of acidic medium (pH 4.5-5.0) in an attempt to resuspend
the small pellets, and then washed 5 times with 1 ml volumes of sterile PBS.
All washings were collected in a sterile stainless steel micro Omni-Mixer cup
and homogenized at full speed for 1 min. in an ice bath. Samples of this acid
precipitate (A.P.) virus homogenate were stored at -8o oc for future assay.
One ml of sterile-filtered CsCI solution (895.3 mg/ml) was pipetted into
each of 6 centrifuge tubes (Beckman® #331370, cellulose nitrate, Beckman
Instruments, Fullerton, CA). One ml of sterile PBS was placed in tube #6 and
1.0 ml of the A.P. virus homogenate was placed in each of the other 5 tubes.
Approximately 11 ml of Nujol® Laxative Extra Heavy Mineral Oil (Plough, Inc.,
Memphis, TN) was placed in each of the 6 tubes. The tubes were centrifuged
in the Beckman® L8-70 ultracentrifuge (Beckman Instruments) at 14°C, 25,000
rpm, slow acceleration, brake off, for 16.5 hours with tubes in their respectively
numbered buckets of the SW41 rotor. After centrifugation, fractions were
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obtained by collecting single drops from a hole punctured in the bottom of
each tube. The fractions were co llected from tube #6 first, and then from each
of the other tubes in the order #1 through #5. A single drop was collected in
each of the 1.0 ml non-sterile polystyrene centrifuge tubes (Fisher Scientific,
Pittsburgh, PA) used to collect from tube #6. The same amount was collected
in each of the sterile Fisher #05-407-5 centrifuge tubes used to collect from
tube #1 . One ml polystyrene centrifuge tubes were used to collect single
drops from tube #2. The single drops collected from each of tubes #3 through
#5 were pooled in sterile Fisher #05-407-5 centrifuge tubes .
Refractive indices of each sample collected from tube #6 were
measured by use of a Bausch and Lomb refractometer (Fisher Scientific). A
Haake type F constant temperature water bath (American Scientific Products,
Sunnyvale, CA) was used to maintain a uniform 25°C temperature on the
refractometer glass plate. The density of each sample was calculated from the
refractive indices by use of the formula of Bruner and Vinograd (1 04) : p25oc =
10.2402 TJ o2soc - 12.6483 for densities between 1.00 and 1.37 g/cm3 , where

p25oc =density at 25°C and TJo25oc = refractive index measurement at 25°C.
The refractive index was corrected for the PBS in the CsCI samples before the
density was calculated.
Tubes containing fractions collected from centrifuge tubes #1 through
#5 were capped and placed at

-sooc

for storage until assays could be

performed.

Protein assay. Protein in each sample was assayed by the Bio-Rad
Protein Assay procedure (Bio - Rad Laboratories, Richmond, CA).

Bovine

plasma gamma globulin was used as a protein standard (Bio-Rad Protein
Assay Standard 1).

Medium. The same types of cell culture medium as those described in
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the materials and methods section of Chapter Ill were used in these
experiments.
Cells. See the materials and methods section of Chapter Ill.
Virus assay. Virus was assayed by the plaque assay method outlined
in Chapter Ill, materials and methods section .
Mice.

Mice were used as described in the materials and methods

section of Chapter Ill.
Neutralizing antibody assay.

Sera of mice were assayed for

neutralizing antibody as explained in the materials and methods section of
Chapter Ill.
Experiments comparing diabetogenicity of crude and purified virus
pools. Male mice received either 4 x 1Q3, 4 x 1Q4 , or 4 x 1as pfu of crude or of
purified virus by the intranasal (i.n.) route while they were lightly anesthetized
by ether. In the first experiment, female mice were included to determine if
they would respond to purified virus differently than the male mice . The
females received only the 4 x 1Q4 pfu dosage from each virus pool by the i.n.
route of inoculation . All mice in this experiment were sacrificed 7 days after
receiving virus in order to determine plasma glucose and neutralizing
antibody levels.
A second experiment was run to determine if additional mice would
develop diabetes when allowed a longer period of time for development of the
disease. Both crude and purified virus preparations were used for infection to
determine if one would be more diabetogenic than the other. The rate of
death and number of diabetes cures were also observed for differences
between crude and purified virus. Mouse sacrifice was delayed from the 7
days of the first experiment to either 9 or 21 days to allow more time for
development of diabetes. Up to 10 mice from each group that had glycosuria
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on day 9 p.i., or that had demonstrated a remission of glycosuria by day 9,
were selected for sacrifice on that day . The other mice in each group were
retained for obseNation over the full 21 days. A 10-fold higher dosage of virus
was given to females in this experiment to determine if increased virus would
cause more females to become diabetic.
The mice of both experiments were monitored daily for glycosuria by
use of Clinistix® (Ames Div. , Miles Laboratories, Inc., Elkhart, IN). After they
were positive by this test , Diastix® (Ames) test strips were used in order to
obtain quantitative results.
Bleeding and plasma sample collection. Bleeding and plasma sample
collection techniques were the same as those in the materials and methods
section of Chapter Ill. The plasma samples were frozen (-80°C) and analyzed
later for glucose and neutralizing antibody, as outlined in the materials and
methods section of Chapter Ill.
Results. Virus purification.

The infectious virus recovered in the

pooled fractions from density gradient tubes 3, 4, and 5 is shown in Fig. IV-1 a.
The virus recovered in each fraction from density gradient tube 2 is shown in
Fig . IV-1 b along with the density of corresponding fractions recovered from
density gradient tube 6.
At each step of the purification procedure, the percentage recovery of
plaque forming units of virus was compared to the percentage recovery of total
protein to obtain a purification index (1 05). These results for sample #25 of
pooled fractions from density gradient tubes 3, 4, and 5 are shown in Table IV-

I. Other samples from the virus peak shown in Fig. IV-1 a provided similar
results. The virus preparations labeled "purified" in these experiments were
approximately 67-fold more pure than the crude virus preparation.
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FIG . IV-1 . Density gradient purification of EMC-D virus. Open squares are
density results of fractions without virus (centrifuge tube #6). Closed squares
are virus titers obtained from fractions (a) pooled from centrifuge tubes #3-5;
and (b) from centrifuge tube #2.

TABLE IV-I. EMC-D VIRUS PURIFICATION.

Sample

Total

Virus

Total

Virus

Protein

Total

Protein

Purification

volume

titer

virus

recovery

cone.

protein

recovery

indexa

(ml)

(pfu/ml)

(pfu)

(%of initial)

(llg/ml)

(llg)

(% of initial)

Crude pool

258

5.4x1 07

1.4x1010

100

1,790

4.6x105

Freon supernate

323

8.4x1 07

2.7x1010

192.8

1,040

3.4x105

73.9

2.6

1.8x1 oJ

0.4

2.8

Acid precipitate

5.5

2.7x107

1.5x1 os

1.1

Density gradientb

0.06

5.7x107

3.4x106

0.02

332 .8
24 .8

1.4

100

0.0003

66.7

a Purification index = percentage recovery of virus+ percentage recovery of protein.
b Density gradient sample #25 from 3-5 pooled tubes was assayed.
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Diabetogenicity of crude and purified virus preparations. The number
of male mice that developed diabetic signs by day 7 post virus inoculation
(p.i. ) was directly proportional to the dosage of virus given whether the virus
was the crude or the purified preparation (Table IV-11). Both parameters for
diabetic signs (glycosuria and plasma glucose) were in agreement in samples
from male mice on the day of sacrifice. Two of 5 female mice given 4 x 1Q4 pfu
of purified virus were diabetic by plasma glucose , but only one had glycosuria
by Diasti x®.

The females given the same dosage of crude virus failed to

develop any signs of diabetes.

All of the female mice which were tested

developed neutralizing antibodies. Only the lowest dosage of virus failed to
infect the male mice sufficiently to cause every mouse to produce antibodies.
At this lowest virus dosage, only those male mice infected sufficiently to
produce circulating antibodies became diabetic.
Glycosuria , plasma glucose, and neutralizing antibody data gathered
from mice sacrificed 9 or 21 days post virus inoculation are summarized in
Table IV-III. Glycosuria data from day 7 are included for comparison with data
from the first experiment. Standard deviations for the mean values of plasma
glucose and neutralizing antibody concentrations are shown in Table A-1 of
the Appendix . Neutralizing antibody data are not combined since the antibody
titers would be expected to be, and were significantly higher in those mice
sacrificed 21 days after infection than in those sacrificed 9 days p.i.
A time-line with events of change , either cure from previous glycosuria
or death , indicated on the days they were observed is depicted in Fig. IV-2.
The type of virus pool and the concentration of virus used in the mice involved
in each event is represented by the location and the type of symbol ,
respectively.
Four mice out of 63 inoculated with crude virus died during the

TABLE IV-11. TITRATION OF CRUDE vs PURIFIED EMC-D VIRUS POOLS.
MICE WERE SACRIFICED 9 DAYS POST VIRUS INOCULATION.
Titer of virus
inoculum
(pfu/mouse)
4

Da}'7
Crude Purified

D~9

Crude Purified

Qrud~

Neutral. antibodyc
(m~an +S.D.)

P!.!rifi~Q

Pos.a/total

Meanb

Pos./total

Mean

Crude

Purified

717

9/10

8/10

9/10

9/10

518±165

9/10

541±180

704±466

555±393

4 X 104

9/10

10/10

10/10

10/10

10/10

593±167

9/9

517±120

597±283

443±309

4

10/10

9/9

10/10

9/10

10/10

567±95

9/10

498±167

354±185

482±209

5/5

10/10

6/6

7/10

358±125

6/6

466±106

458±248

627±508

X

X

103

Plasma gii.!QQS~ (da}' 9)

GI}'QQS!Jria (pQS.l!Qlal)

105

4 x 105 female 10/10

a <!3 S.D. above the mean plasma glucose concentration of control mice.
b mg/100 ml {±S.D.)
c Units/0.1 ml of plasma.

(J)

w

TABLE IV-III. TITRATION OF CRUDE vs PURIFIED EMC-0 VIRUS POOLS.
MICE WERE SACRIFICED
Titer of virus
Inoculum
(pfu/mouse)

4 X 103

4 X 104

4 X 105

4 x 105 female

0

!iced on
(day)

DAYS POST VIRUS INOCULATION.

~!da(llQSllQ!aD

Data from

mice sacri-

9 OR 21

Cl<ri9

DiltZ
Puritied

Crude

Crude

ElaSI]l;l~Wif:
Da~Zl

Puritied

Crude

Puritied

Cold!:
Pos.a/
total

Ewi!ied
Pos./ Mean
total

Meanb

Neutralizing
aotibQQJf
Crude Purified

9
21
Combined

717 ..
911o··
2/3 ••
0/5
7/12 •• 11/13 ••

511o·· 911o··
2/3 ••
0/5
8/15 •• 11/13 ••

0/5

2/5.

911o·· 515••
0/5
182
9115•• 406 ••

911o·· 541··
308.
2/5.
11/15 •• 463 ••

704
1120

556
1313

9
21
Combined

911o·· 1011o··
4/4 ••
2/3 ••
11113•• 14/14••

1011o·· 1011o··
4/4 ••
1/3
11/13•• 14/14 ••

1/3

3/4 ••

1011o·· 593··
2/3 •• 371
12/13 •• 542 ••

9/9d·· 517""
3/4 ••
459 ••
12113 •• 499 ••

597
2933

443
1651

9
21
Combined

10/1o·· 9/9 ••
4/4••
515··
14/14•• 14/14 ••

1011o·· 911o··
4/4 ••
2/4.
14/14•• 11/14 ••

3/4 ••

1/3

10/1o·· 567 ••
3/4 •• 512 ••
13/14•• 551 ••

911o·· 495••
1/3
392
10/13 •• 473 ••

354
3203

482
1731

9
21
Combined

1011o··
2/6.
12/15••

017

0/12

111o·· 355••
0/6d
170
7/16.. 287 ••

616 ••
466 ••
0/11d 161
6/17 •• 269 ••

458
1613

627
1878

9
21
Combined

515··
0/5
511o··

0/19
0/10
0/29

1011o··
1/4
11/14••
0/19
0/10
0/29

6t6••
0/5
6/11 ••

0/10

0/19
019d
0/28

174
166
171

0
0
0

a ~3 S.D. above the mean plasma glucose concentration of control mice.
b mg/100 mi.
c Units/0.1 ml of plasma.
d Sample not available from one mouse.
• P<0.05 ;

•• P<0.01; compared to controls.
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Fig. IV-2. Time-line diagram of cures or deaths in mice inoculated with crude or purified preparations of EMC-D virus.
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experiment. The mean day of death for these mice was 7.0 ± 2. 7. Although
the cause of death was not determined, it did not seem to be due to central
nervous system infection because the mice that died did not show obvious
signs of paralysis. A general parenteral infection by the virus would seem
more likely. Three of the mice were noted to have a bright red and swollen
penis just before death. One of the mice had a bloody penis. In general , the
mice suddenly appeared very ill , and died within 1 or 2 days. Of the 59 mice
(42 males and 17 females) that lived to provide a blood sample , 3 failed to
produce circulating antibody specific for the virus. All 3 of these mice were
males that had been inoculated with 4 x 103 pfu of crude virus. One of these
antibody-negative mice was sacrificed on day 9 and the other 2 on day 21 p.i.
Five of the 65 mice inoculated with purified virus died prior to day 21 ,
with a mean day of death of 9.2 ± 3.1. All of the 59 mice that provided enough
blood to test (1 diabetes-negative female sacrificed on day 21 provided
insufficient blood for the antibody assay) had

~ 80

units of antibody /0 .1 ml of

plasma.
None of the mice that died during the experiment developed glycosuria
which remitted before death. However, 2 of the male mice that died (days 8
and 12) appeared to be progressing toward remission just prior to death , in
that the concentration of glucose in their urine samples was decreasing . Both
of these mice had received purified virus. Two other male mice that died (days
9 and 13) were also positive for glycosuria at the time of their deaths. One of
these mice had received 4 x 104 pfu of crude virus and the other had received
4 x 105 pfu of purified virus. The 3 mice that died prior to day 8 had never
developed glycosuria, and the 3 that died after day 8 were all glycosuric at the
time of death. The 3 mice that died on day 8 included 2 without glycosuria and
1 with glycosuria.
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Five of the mice given crude virus spontaneously recovered from
glycosuria before they were sacrificed. The mean day of cure for these mice
was 10.8 ± 3.0. Four mice which were given purified EMC-D virus recovered
with the mean day of cure being 9.2 ± 1.9.
Discussion. The greatest purification ratio for the EMC-0 virus was
obtained within the peak area of infectious virus in the density gradient
centrifugation . The virus within that peak was approximately 67 times more
pure than was the crude pool.
Most of the data was statistically significant when infected mice were
compared to uninfected control mice, as seen in the P values given in Tables
IV-II and IV-III. When crude virus-infected mouse data was compared to data
from mice infected with purified virus, there was no statistically significant data
(P :-;; 0.05). The number of male mice which developed diabetic signs was not
statistically different (P > 0.05) according to the purity of the virus. These
differences also varied according to virus dosage and according to experiment
performed, but not to an extent to make them statistically significant. Female
mice were less sensitive to the diabetogenicity of the virus . Their lack of
diabetic signs was not due to an ability to prevent a generalized infection by
the virus, since each of the female mice tested for circulating antibodies had
titers

~1

00 units/0.1 mi. When the virus inoculum was increased 10-fold, the

percentage of female mice which developed diabetes was nearer to that of the
male mice. In fact, in the case of higher virus inoculum, the only statistically
significant difference (at P :-;; 0.05) between the number of males and females
that developed diabetes was when purified virus was used and numbers of
mice with glycosuria at 7 days p.i. were compared.
The crude and purified virus preparations were almost equally
infectious as judged by the number of mice that developed neutralizing
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antibodies. It is interesting that all of the mice that failed to develop detectable
circulating antibodies specific to the virus also did not develop diabetic signs ;
however, the development of circulating antibody alone was not sufficient to
cause diabetic signs. Some of the mice with very high antibody titers, as high
as 1920 units/0.1 ml, also had negative tests for glycosuria and their plasma
glucose concentrations were very near, or even below, the mean
concentration found in control mice.
The extended time between infection and sacrifice did not increase the
percentage of male mice which became diabetic, regardless of the virus pool
used for infection. None of the mice became diabetic between day 9 and day
21 p.i. Only one of the female mice apparently became glycosuric between 7
and 9 days p.i., and that could have been an artifact due to a history of no
urine samples prior to day 9. Some mice recovered from the diabetic state
after day 7 p.i. The reasons for recovery of some mice when others remained
strongly diabetic is not known.
No significant differences in the numbers of mice reversing to normal
from glycosuria could be seen when either crude or purified preparations of
virus were used. Equal numbers of animals died or went into remission during
the experiment. Most of the animals which reversed from glycosuria or died,
did so within 9 days of introduction of the virus; however, some changes were
seen as long as 15 days after virus inoculation (Fig. IV-2).
The relative frequencies of male mice which died was somewhat dose
dependent in that none given 4 x 103 pfu of virus died, but equal numbers
died when given either 4 x 104 or 4 x 1os pfu. Unexpectedly, the male mice
given the highest dose of virus were also the ones that had the highest cure
rate (14.8%). Those given 4 x 104 or 4 x 103 pfu of virus had lower cure rates
(7.4% and 6. 7%, respectively). The differences in recovery rates were not
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statistically significant. The mice were able to cure themselves in a way that is
not understood.
The death rate of mice given 4 x 1as pfu of virus was slightly higher
(4/35) when purified virus was used to infect than when crude virus was given
(2/33) . The cure rate for mice given 4 x 1as pfu of purified virus was also

higher (3/3a) than when crude virus was given (2/31 ). These differences were
not statistically significant.

Conclusions. Additional mice were not found to become diabetic
during the extended time between infection and sacrifice. In fact , just the
opposite occurred. Some mice that had been diabetic by glycosuria early in
the experiment spontaneously recovered and returned to normal during the
extended time period. These mice evidently retained some functioning beta
cells that were able to regenerate sufficiently to produce adequate levels of
insulin . It is possible that even more cures would have occurred if many of the
glycosuric mice had not been sacrificed on day 9 p.i. There was no significant
difference in remissions from diabetes when the use of crude virus was
compared to that of purified virus.
No extraneous (non-infectious viral or cellular) material was shown to
contribute to, or oppose, the diabetogenic capabilities of EMC-D virus. There
were no statistically significant differences in the numbers of mice that died,
showed remission from glycosuria, developed diabetes, or developed
antibody to the virus when either crude or purified virus was used for infection .
Titration of each type of virus pool (crude or purified) yielded approximately
equal numbers of mice in each of the categories above, when equal
concentrations of virus were used from each type of pool. Thus , it seems that
the infectious EMC-D virus particle is intrinsically diabetogenic. However,
purification of the virus sufficient to remove all of the cell material from the
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preparation would be necessary to absolutely prove that cellular material does
not play a part in the diabetogenicity of EMC-D virus.
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CHAPTERV
HOST DEFENSE ACTIVITIES IN
RELATIONSHIP TO DIABETES
INDUCED BY EMC-D VIRUS

Introduction. Previous investigators have demonstrated a variety of
different characteristics that affect the outcome of EMC virus infection of mice,
especially relating to whether or not diabetes is induced in the animal. It is
impossible to determine the characteristics that are necessary for the infection
to lead to diabetes because of the many conflicting results obtained by these
investigators. However, host defense mechanisms appear to be one group of
characteristics that is consistently important in the outcome of this infection.
This study was designed to obtain additional information regarding what is
occurring to selected host defense mechanisms at the time virus infection is
inducing the diabetic state in mice.
Many strains of mice have been shown to be resistant to the
diabetogenicity of EMC virus. Boucher et al. (66) recognized a genetic trait of
resistance and Yoon and Notkins (67) attributed the inherited trait to a
resistance of the beta cells of the pancreas to infection by EMC virus.
However, experiments by Dafoe et al. (72) demonstrated that host factors
other than inherited pancreatic resistant factors are most important in
determining susceptibility to the diabetogenicity of EMC virus.
Testosterone has been shown to be very important in causing mice to
become susceptible to the diabetogenicity of EMC virus, at least in certain
strains of mice (73). Giron and Patterson (74) found that females of one strain
of mouse (DBA/2J) remained resistant to EMC-D-induced diabetes when
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treated with testosterone even though ICR Swiss female mice became
susceptible when treated with testosterone.
Giron et al. (75) also found that ICR Swiss mice must be older than 7
weeks for EMC·D virus to induce diabetes. In mice younger than 7 weeks, the
virus induced a lethal encephalitis instead of diabetes.
Yoon et al. (15) speculated that differences in IFN-stimulating ability of
their 8 and D variants of EMC virus could account for the differences in
diabetogenicity exhibited by the two variants. They found that the D variant,
which caused near 100% of the mice injected to develop diabetes, stimulated
little, or no, IFN production in either cell culture or mice. The 8 variant, with
near 0% diabetogenicity, had the opposite IFN·stimulatory ability , with normal
levels being stimulated in both cell culture and mice.
IFN or its inducers have different effects on the diabetogenicity of EMC·
D virus , according to results reported by others (17, 18). While IFN· B, or a
variety of IFN inducers, blocked the diabetogenic effect of the virus in SWRJJ
mice, no effect was seen in ICR Swiss mice when the same treatments were
used according to a report by Giron's group (17) . The same group (18)
extended the studies and reported that if IFN·B or IFN·Y were given at a
specific time in the infection, it exacerbated the diabetogenic nature of the
virus.
Earlier investigators (19, 20 , 76) reported that the cellular immune
system must be functional for EMC strain M virus to cause diabetes. They also
found that diabetes is caused even in the absence of a funct ional humoral
immune system .
Each of these prior findings emphasizes that the diabetogenicity of
EMC virus is certainly affected by the resistance mechanisms of the mouse.
Exactly how these mechanisms influence the course of development of the
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diabetic syndrome has not been elucidated. The research reported here was
undertaken with the goal of discovering what happens to some of the
resistance mechanisms of the mouse during induction of the diabetic state by
EMC-D virus infection.

Materials and Methods. Mice. Male SJUJ mice were used in these
experiments. They were obtained and maintained as outlined in Chapter Ill.
Medium, cells, and virus. All were explained in Chapter Ill.
Titration of animal serum for neutralizing antibody. These titrations
were done in a manner similar to that outlined for mouse plasma samples in
Chapter Ill.
Titration of interferon. Samples were titered in a manner similar to that
outlined in Chapter Ill for the titration of poly I:C-induced IFN with the following
exceptions: 1) Only L-cells were used for the titrations. 2) Three wells, instead
of four, were used for each dilution. and 3) The plates were incubated for only
22 hr at 37°C before the samples were aspirated from the cells and 0.1 ml of
virus (VSV only) was placed in each well.
Plaque assay of density gradient samples. Plaque assays to determine
the concentrations of EMC-D virus present in density gradient samples were
carried out as described in the materials and methods section of Chapter Ill.
Comparison of diabetic signs with signs of EMC infection at various
intervals. Male SJUJ mice were inoculated by the i.n . route with the L-cellpassaged virus at a concentration of 4 x 1as pfu/mouse or with an equal
volume (20 J.!l) of sterile virus diluent for control mice. At various intervals from
0 to 125 hr after virus exposure, mice were sacrificed by bleeding and tissue
samples were taken; some samples were frozen and some were fixed in
buffered 10% formalin, for future analysis. Analyses were made of the urine
samples taken at the time of sacrifice by use of Clinistix®; Diastix® were used
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after the Clinistix® tests were positive . Two mice exposed to virus and one
control mouse were sacrificed at each interval.
Titration of infectious virus from mouse tissues. Tissues stored at -80°

were weighed, thawed and homogenized in sufficient test medium to prepare
a 10% (w/v) suspension . In some cases, especially with lung and thymus
tissues, only a 5% suspension was made because there would have been
insufficient volume for the homogenizer to function if a 10% suspension had
been made.
The tissue homogenates and plasma samples were diluted in test
medium by serial 10-fold dilutions. One-tenth ml of each dilution was placed
in each of triplicate wells of a 96-well plate containing monolayers of L-cells.
The plates were wrapped with Saran Wrapn.c (The Dow Chemical Co.,
Indianapolis, IN), incubated at 37° C for 3 days, and the CPE was read by use
of an inverted microscope . Virus titers were calculated by the 50% endpoint
method of Reed and Muench (94) and expressed as cell culture infectious
dose, 50% endpoint (CCIDso)/0.1 mi.
Guinea pig serum collection.

Guinea pigs were bled by cardiac

puncture after they had been anesthetized by intramuscular (im) injections of
VETALAR® (Ketamine HCI Injection, NF) Veterinary--equivalent to 100 mg/ml
Ketamine (Parke Davis and Co., Detroit, Ml) plus Acepromazine (1 :10).
Collected blood samples were placed in 15 ml sterile Corning centrifuge tubes
(Corning Glass Works, Corning, NY) and allowed to clot.

Each clot was

rimmed with a wood applicator stick and the tube was centrifuged to separate
the serum , which was collected and frozen for future assay.
Preparation of primary antibody specific for EMC-0 virus. Virus was

pu rified by CsCI density gradient as outlined in Chapter IV with the following
changes:

1) Four and one-half ml of CsCI was used in each of 4 tubes. 2)
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Four and one-half ml of sterile PBS was added to 2 of the tubes and 4.5 ml of
the virus to each of the other 2 tubes (tubes 1 & 4 of the ultracentrifuge) . 3)
The tubes were centrifuged at 35 ,000 rpm for 38.5 hr. 4) Both virus-containing
tubes had a visible, ragged-looking heavy band approximately half way down
in the gradients of each tube. This precipitate, which looked as though it were
protein , was collected mainly in fractions numbered 9 & 10. However, the
precipitate was seen to form a very narrow "stream" down the center of each
tube as fractions were beginning to be collected. The visible "stream" reached
the bottom of the tube at approximately the time that fractions 4 and 5 were
being collected.
As the fractions were being collected from tube #1 and the precipitate
reached the collection needle, it plugged the needle until sufficient pressure
was applied to suddenly break the plug loose. The drops flowed so rapidly
from the tube that two fractions (20 drops) were collected in fraction tube #9.
The very rapid flow caused some visible mixing action at the very bottom of the
density gradient tube.
The fractions obtained from the density gradient tubes were titered by
plaque assay to determine which samples contained the highest
concentrations of infectious virus. The samples with peak virus titers (#1-8,
#1-9, #4-8, and #4-9) were selected for dialysis. The first number represents
the density gradient centrifuge tube number from which fractions were
collected. The second number represents the fraction number collected from
that centrifuge tube, i.e. #1-8 is fraction number 8 collected from centrifuge
tube number 1. These samples were diluted 1:10 in sterile 5 mM phosphate
buffered saline, pH 7.3 (PBS-1) and dialyzed against PBS-1.

All dialyses

occurred at 4°C with stirring. The first dialysis was for 2 hr in 500 ml of PBS-1,
the second for 4 hr in 500 ml of fresh PBS-1, and the final dialysis was for 19
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hr in 1,000 ml of fresh PBS-1. The samples were removed from the dialysis
tubing and placed in freezer vials for storage at -80°C. All samples were clear
except #1-9 , which had a white precipitate.
Portions of sample #4-9 were diluted 1:3 in sterile PBS-1 and in 10%
buffered formalin. The sample diluted in PBS-1 was placed at 49°C for 15 hr
for heat inactivation (4-9-11) and the sample in formalin (4-9-formalin) was
placed at 4°C for an equal time period to allow inactivation by formalin action.
Sample #1-9 was diluted 1 :16 in sterile PBS-1 and placed at 49°C for 15 hr for
heat inactivation (1-9-11) . Samples of 1-9-11, 4-9-11, and 4-9-formalin were
placed on L-cells to determine if complete inactivation had occurred. Neither
of the heated samples was completely inactivated, so they were additionally
heated at 55°C for 20 hr, which completely inactivated the virus infectivity in Lcells. The formalin-treated sample was completely inactive in L-cells.
Three female Hartley guinea pigs were used. One of the guinea pigs
received 0.3 ml of an equal volume mixture of 1-9-formalin and Freund's
complete adjuvant (FCA) (Calbiochem-Behring Corp., LaJolla, CA) in each
rear flank by the im route. The mixture was made by forcefully injecting the
FCA into the virus preparation, which was already in a serum vial. The mixture
was pulled into the syringe and forcefully injected back into the vial 2 times.
The resulting milky-white suspension was used for injection . The two heatinactivated virus samples were mixed in equal volumes with FCA, as outlined
above. These suspensions were injected im into each of the other two guinea
pigs. The next day, one of the latter 2 guinea pigs was found dead and 2 days
later, the second guinea pig that had received heat-inactivated virus died.
Two male Hartley guinea pigs were bled. One was injected im with a
sample of heat-inactivated virus, without adjuvant, while the other received a
formalin-inactivated virus sample im without adjuvant. The guinea pigs were
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bled and given booster shots on somewhat different schedules, as shown in
Table V-1.
Sample #1·9 from the density gradient centrifugation was emulsified
with an equal volume of FCA by repeatedly (approximately 20 total syringe
pushes) forcing the mixture between 2 syringes (5 ml) connected by 16 gauge
x 1.5" needles and silicone tubing. When a drop of the emulsion on water
held a bead, it was considered sufficiently emulsified (1 06).

This emulsion

was immediately injected into the gluteal muscles of a New Zealand White
male rabbit. Approximately 2.6 ml of the emulsion was divided into 4 injection
sites, 2 on each side of the rabbit.

The virus was not inactivated in any

deliberate manner prior to injection. The rabbit was bled and boosted with
virus injections as summarized in Table V-11.

Serum collection from rabbit.

The outside of the chosen ear was

clipped closely by use of electric clippers. Xylene was rubbed on the central
ear artery and the artery was vigorously rubbed from the base of the ear
toward the tip with a dry cotton ball. A sterile 20 gauge x 1" injection needle
was inserted into the upper end of the artery with the needle pointed toward
the head of the rabbit. Blood was allowed to flow from the needle hub into a
sterile Venoject® AutoSep,.,. tube with inert separator gel and clot activator
(Terumo Medical Corp., Elkton, MD).

Immediately after the blood was

collected, a sterile cotton swab was pressed tightly over the hole left when the
needle was withdrawn, and held until a clot stopped the bleeding. The ear
was then thoroughly washed with warm water and baby shampoo.

After

thoroughly rinsing and drying the ear, Sulfa Urea Ointment (Veterinary
Laboratories, Inc., Lenexa, KS) was applied and rubbed into the skin of the
ear. Alternate ears were used with each successive bleeding when this was
possible.

The blood was allowed to clot at room temperature and then
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TABLE V-I. GUINEA PIG INJECTION AND BLEEDING SCHEDULES
AND ANTIBODY TITERS.

Pig no.

Action

Number of days from initial antigen inoculation

Bleed

0

lnjecta

Ob

2

Bleed

0

Inject

oc

3

Bleed

-1

26

34

Tit ere

0

1.0

1.0

Inject

ot

269

519

Bleed

-1

33

42

71

Titer
Inject

0
Qk

34k

sam

1.3
79m

Bleed

-8

13

34

78

92

163d

Titer

0
on

0

0

0

0

nm

86P

4

5

Inject

dead on day 4
dead on day 1

26n

117

158

188d

1.0
111 h 152h

3.4
18Qi

4.2

60

dead on day 83

a All injections by im route unless otherwise stated in footnote.
b

4-9-6 + Freund's Complete Adjuvant.

c 1-9-6 + Freund's Complete Adjuvant.
d Sacrificed
e Log1o neutralizing antibody titer (0 indicates no antibody detected) .
t 4-9 -formalin

+ Freund's Complete Adjuvant.

9 4-9-formalin no adjuvant.
h 4-9, live virus, no adjuvant.
i 4-8, live virus, no adjuvant.
k 4-9-6, no adjuvant.
m EMC-D, crude pool, 1Q5.9 pfu given by i.n. route.
n 1-9-formalin, no adjuvant.
P Both EMC-0, crude pool by i.n. route and 1-9-formalin, no adjuvant.

TABLE V-11. RABBIT INJECTION AND BLEEDING SCHEDULES AND NEUTRALIZING ANTIBODY TITER.

Action
Bleed
Titera
Inject

Number of days from initial antigen inoculation
-4

3

10

17

24

31

38

59

63

416 418

n.d.b 1.53 4.31 3.63 3.54 3.91 3.86 3.85 3.57 3.00 3.08

oc

21d

31e

59'

4169

420 422

427 431

437 452

456

466

4.15 4.30 4.30 4.15 4.1 5 4.30 4.15
452h

a Neutralizing antibody titer (log1o units/0.1 ml) .
b None detected.
c 1-9 (live), (0.5 ml + 1.0 ml PBS , emulsified with 1.5 ml Freund's complete adjuvant), 2.6 ml by im injection.
d 4-9 (live), 0.5 ml undilute by iv injection.

e 4-9 (live), 0.25 ml undilute by iv injection.
t 1-9 (live), 0.1 ml undilute by sc injection.

g EMC-0, Pur. #1, 9-27-85 (live), 1.0 ml of a 1:10 dilution by iv injection.
h EMC-0, Pur. #1, 9-27-85 (live), 1.0 ml of a 1:10 dilution by iv injection.

-...J
<0
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centrifuged at the highest speed setting of an International clinical centrifuge
(International Equipment Co., Needham Heights, MA) for 5 minutes . The
serum was collected from the top of the plug and dispensed to freezer vials
which were placed at -80°C or stored at refrigerator temperature for later
assay of antibody in the serum.
Separation of lgG from lgM and other serum components. ZetaChrom"'
60 D1 Amine Disks (AMF Laboratory Products, 400 Research Parkway,
Meriden, CT) were utilized as outlined in the product use brochure supplied
with the disks. In brief, the process was as follows. The sample of serum was
diluted 1:10 in "Buffer A" (0 .015M NaH 2 P0 4 , pH 6.3, conductivity 1.0 milli
mho/em) . The ZetaChrom 60 disk was equilibrated by washing it with 75 ml of
"Buffer B" (0 .1M NaH 2 P0 4 , pH 6.8, conductivity 9.0 milli mho/em) and then
passing 75 ml of Buffer A through the disk. The sample was applied to the
disk by use of a syringe with the flow rate adjusted to 5-10 ml/min. The effluent
from the disk was collected as purified lgG. The disk was washed with an
additional 28 ml of Buffer A to remove all of the lgG . Bound proteins, including
lgM, were eluted by passing 50 ml of Buffer B rapidly through the disk. From
the time the sample was applied until the entire 50 ml of Buffer B was pushed
though the disk, 4.0 ml fractions were collected as disk effluent. The O.D. (at
280 nm) of each fraction was read on a Perkin-Elmer, Coleman 124 double
beam spectrophotometer (Hitachi Ltd., Tokyo, Japan). using 1 em cuvettes.
Each sample was titered for neutralizing antibody.
Other primary antibody preparations. Anti-porcine insulin prepared in
the guinea pig was obtained from Miles Scientific Division, Miles Laboratories,
Inc., Naperville, IL. Rabbit anti-mouse IFN (alpha) antiserum was purchased
from Chemicon International, Inc., Los Angeles, CA. Anti-mouse IFN (beta)
globulin raised in a rabbit was purchased from Lee BioMolecular Research
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Laboratories, Inc., San Diego, CA.

Rabbit anti-mouse IFN (gamma) was

obtained from Enzo Biochem , Inc., New York, NY.
Immunohistochemical staining. Tissue sections, 7

~m

th ick, were

prepared by the Animal , Dairy, and Veterinary Science diagnostic group,
using mouse tissues that had been placed in 10% buffered formalin solution
after they were freshly excised from the mice. The tissues were stored in this
solution until they were embedded and sectioned. The sections were placed
on glass slides without gelatin or other added material to fi x the section to the
slide.

It is important that certain adherence factors, especially gelatin, be

avoided since these can cause a strong false positive background staining
(Vectastain® Product Insert).
The

Vectastain ® ABC immunoperoxidase staining procedure

(Vectastain ABC Kits, Vector Laboratories, Burlingame, CA) was generally
followed but some major adjustments were made to avoid the non-specific
staining initially experienced .

The following procedure was found to be

satisfactory. The sections were deparafinized by soaking in 3 separate baths
of Histosol (National Diagnostics, Somerville, NJ) for 2 minutes in each .
Hydration of the tissues was accomplished by 2 separate baths of absolute
ethanol (EtOH) for 30 seconds each, then 2 baths of 95% EtOH (30 seconds in
the first and 10 dips in the second), 10 dips in a 50% EtOH bath , 10 dips in a
tap water bath and 5 minutes in a distilled water bath . Blocking serum (1 .8%
normal serum from a species of animal in which the secondary antibody was
made) was flooded over the tissue sections and the slides were placed in a
humidified chamber to incubate for 20 minutes at room temperature (all steps
took place at room temperature). Excess serum was blotted from the slides
and primary antibody used to flood the tissue. The slides were again placed
in the chamber for 30 minutes. The sections were rinsed for 10 minutes in
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1OmM phosphate-buffered saline, pH 7.6 (PBS-2) and the slides were
incubated for 30 minutes with diluted biotinylated antibody solution.

The

slides were again rinsed for 10 minutes in fresh PBS-2 and incubated for 30
minutes with Vectastain ® ABC reagent. The slides were rinsed for 10 minutes
in fresh PBS-2 and exposed for 10 minutes to the peroxidase substrate
solution (3 20 ml of 50mM Tris buffer, pH 7.6 ; 9.3 g NaCI ; 160 mg 3,3'diaminobenzidine tetrahydrochloride [DAB]; 1.6 ml 8% NiCI 2 ; all filtered
through Whatman #2 paper, then immediately before use 43 Ill of 30% H2 0 2
was added, with mixing). The slides were rinsed in tap water for 5 minutes
and placed in methyl green/pyronin counterstain for 1.5 minutes. The tissues
were rinsed and dehydrated before cover slips were mounted . Rinsing and
dehydration steps were accomplished by ten dips in each of distilled water,
acetone (2 baths) , acetone/Histosol (50:50) , and Histosol. The slides were
placed in a fresh Histosol bath until cover slips were mounted with Permount
(Fisher Scientific, Pittsburgh , PA) .
Histogen® immunohistology kits (BioGenex Laboratories, Dublin, CA)
were used for some of the staining . In this procedure, the tissue sections were
deparafinized by soaking in 2 separate baths of Histosol for 3 minutes each.
The tissues were hydrated by 2 separate baths of absolute EtOH, 3 minutes
each, followed by 2 baths of 95% EtOH, 3 minutes each, and finally 5 minutes
in 10 mM potassium phosphate buffered saline, pH 7.6 (PBS-3) . Blocking
serum was placed on the tissues for 20 minutes at room temperature (all
incubations took place at room temperature) . Excess serum was removed and
primary antibody was placed on the slides for 30 minutes. The slides were
rinsed well in PBS-3 and link antibody (streptavidin-labeled antibody specific
to the lgG of the species in which the primary antibody was raised) was
allowed to react for 20 minutes. The slides were rinsed again in PBS-3 and
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labeling reagent (biotinylated peroxidase) was flooded over the slides for 20
minutes.

The slides were rinsed well with PBS-3 and freshly prepared

substrate solution was placed on the slides for 5-40 minutes. The slides were
rinsed with glass distilled water, counterstained with hematoxylin, and cover
slips were mounted with aqueous mounting medium .

Results. Diabetic signs compared to virus yield and resistance
parameters at various time periods. Mice infected i.n. with EMC-D virus were
killed at varying times post inoculation (p.i.) and various disease signs were
assayed .

Three parameters of infection and resistance , virus yield, IFN

induction, and neutralizing antibody production, are depicted graphically in
Fig . V-1 as they developed at various times in the plasma of infected mice.
Infectious virus was not detectable (< 1oo.7 CCID 50/0.1 ml) in the plasma until
11 hr p.i., but achieved a peak titer of 1os.4 CCID 50 /0.1 ml at 54 hr, and
declined to non-detectable levels by 125 hr p.i. The plasma IFN activity was
undetectable until 29 hr, then reached a maximal level by 35 hr, declined
slightly in titer between 35 and 96 hr, and dropped to undetectable levels at
125 hr p.i.

Neutralizing antibody began to show detectable levels in the

plasma as early as 72 hr after virus inoculation and continued to increase in
titer through the end of the experiment, 125 hr p.i.
Diabetic signs are represented by plasma glucose levels in Fig . V-2.
The concentrations rose sharply from the normal level (below 200 mg/1 00 ml)
to well above normal between 96 and 125 hr following i.n . introduction of the
virus. Glycosuria was seen in one of the virus-infected mice at 96 hr p.i. This
mouse was not sacrificed to obtain plasma glucose measurements until 125 hr
p.i.
Results of virus, IFN, glucose, and neutralizing antibody in blood
plasma are combined from 2 experiments.

One of the experiments had
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FIG. V-1. Comparison of virus, IFN, and neutralizing antibody concentra!ions in the plasma of mice at various times after inoculation of EMC-D virus by
the i.n . route. Male SJUJ mice were inoculated with virus and two mice were
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. Single control mice (receiving virus diluent only) sacrificed

at each time period were uniformly negative for tested items in the plasma.
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sample times ranging from 0 to 71 hr post-virus inoculation and solid tissues
were taken for analysis of virus as well as for immunohistochemical staining .
The other experiment had sample times ranging from 0 to 125 hr post-virus
inoculation and solid tissues were taken only for immunohistochemical
staining .
Although the virus concentration in the plasma of the mice was
reduced somewhat by 71 hr p.i., the concentration in other tissues seemed
generally to be increasing at this time, as seen in Fig. V-3. Only the thymus
tissue, in addition to the plasma, seemed to have reached a peak of virus
concentration prior to 71 hr p.i.

Primary antibody specific for EMC-0 virus. Results of virus titrations of
density gradient samples of the virus preparation partially purified for antibody
stimulation are shown in Fig. V-4. The peak virus titer occurred in the sample
with a density of approximately 1.36. Neutralizing antibody titers in the sera
collected from the guinea pigs are shown in Table V-1. One of the guinea pigs
developed a peak antibody titer of 1o4.2 units/0.1 ml of serum. Table V-II gives
neutralizing antibody titers of serum samples obtained from the rabbit. The
highest titer reached was 1Q4.31 units/0 .1 ml of serum .

Results of lgG

separation from other serum components and titrations of neutralizing
antibody in the serum samples of the rabbit are shown in Fig . V-5. The highest
titer of neutralizing antibody was found in the lgG peak.

However, the

neutralizing antibody found in the lgM peak was approximately half as
concentrated as that seen in the lgG peak fraction .

Immunohistochemical staining with anti-insulin primary antibody. Islet
cells stained very prominently in pancreas tissue of control animals and of
virus-infected mice until 54 hours post-inoculation . At this time and after, the
stain ing became spotty, Fig. V-6, or disappeared altogether in tissue sections
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FIG . V-6 . Immunohistochemical staining of insulin (dark brown) in
pancreatic tissue. (A) Section from an infected mouse at 54 hr p.i. Stained
with Vectastain ® ABC kit, guinea pig anti-porcine insulin used as primary
antiserum . (B) Section from a control mouse ; stained as above except that
primary antiserum was omitted, as a negative control.
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from virus infected animals. Sections of pancreas from control animals had
islets that stained strongly throughout the 125 hr of the experiment. Pancreas
tissue of mice infected with EMC-D virus and sacrificed 125 hr p.i. either
completely lacked recognizable islets or the few islets present were devoid of
stain.
Immunohistochemical staining with anti-EMC-0 virus primary antibody.

No specific staining of any tissues could be demonstrated with the guinea pig
antiserum used as primary antibody, nor could any be demonstrated when the
rabbit antiserum was used. However, when rabbit lgG isolated from the antiEMC-D virus antiserum was used as primary antiserum, specific staining of
spleen tissue could be seen which began at 11 hr and showed staining
through 71 hr p.i. No other tissue was specifically stained when the rabbit lgG
was used as primary antibody. Uninfected control mice had no staining of any
tissue.
Staining with antibody specific for the three different types of mouse
IFN.

Immunohistochemical staining for

IFN - ~

in the tissue sections seemed

specific since sections treated with negative control serum instead of primary
antiserum completely lacked stain in all tissues. However, when glandular
tissue (pancreatic acini or tubular glands of the small intestine) was exposed
to the primary antibody and stained, some nuclei were seemingly nonspecifically stained. Even control mice had tissues which stained well. The
virus infected mice appeared to have darker staining tissues than tissues from
control mice. The antiserum had a fairly low titer so that only 1 :20 or 1:40
dilutions could be used.
Tissues exposed to negative control serum also did not stain when
staining was done for IFN-a in the tissue sections. The only cells that stained
in lung tissue when anti-IFN-a was used as primary antibody were smooth
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muscle cells surrounding some of the larger airways. Tissues from uninfected
control mice as well as virus infected mice had areas of plasma which stained
quite well. The anti-IFN-a serum caused positive staining when diluted as
much as 1 :100 or 1:500.

If diluted 1:1,000 or more the endpoint was

surpassed.
Staining patterns for IFN-y was surprising in that thymus and spleen
tissues from control mice stained a little more intensely than the same types of
tissue from virus infected mice. Other tissues had uniform intensity of staining
between tissues of control or virus infected mice. The staining seen in kidney
tissue is represented in Fig. V-7. The anti-IFN-y antiserum could be diluted
1:1,000 or 1:5,000 to obtain intense staining .

Discussion. Experiments to determine the time of appearance of
diabetic signs in mice relative to the signs of EMC virus infection showed that
plasma glucose was not elevated until after infectious virus in the plasma was
eliminated and neutralizing antibody was rapidly increasing in concentration .
In this i.n. infection with a dose of virus designed to cause 100% of the mice to
develop diabetes, the circulating IFN response pattern was very similar to that
described by Yoon et al. (15). Their data indicated that the IFN titer peaks later
and is sustained over a longer period than that seen in mice infected with the
non-diabetogenic EMC-B virus.
Of the 8 tissue types examined (blood , pancreas , spleen , kidney, liver,
lung , heart, and thymus) , only blood and thymus reached peak virus titers in
the 71 hr period studied. Titers in the thymus peaked at 47 hr and blood titers
peaked at 59 hr.

Since the virus was introduced by the i.n. route, it was

surprising that virus appeared in pancreas, liver, blood, and thymus tissues
before it was detected in lung tissue. Virus was not measurable in lung tissue
until 23 hr p.i., whereas virus was detected in pancreas and liver as early as 4
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8

FIG. V-7. Immunohistochemical staining of mouse IFN-r in kidney tissue.
(A) Section from a control mouse with specific staining (red) associated with
the glomerulus. Stained with Histogen® kit, rabbit anti-mouse IFN-r used as
primary antiserum . (B) Serial section from same mouse ; stained as above
except that primary antiserum was omitted, as a negative control.
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hr p.i. and in blood and thymus at 11 hr p.i. Spleen and kidney tissue had
detectable virus as early as lung tissue. Heart tissue was the last tissue type
(at 35 hr p.i.) to begin yielding detectable virus. This was also a surprise since
the virus had initially been cultivated repeatedly in mouse heart tissue to
obtain the M-strain of EMC virus.

These results indicate that free virus

transport in circulating plasma is abating well before diabetic signs begin to
appear.
Only one of the mice had glucose in the urine by 96 hr p.i., and that
mouse was spilling even more glucose the next day when it was sacrificed
(1 000 mg/100 ml at 96 hr and

~2000

mg/100 ml at 125 hr). It is possible that

some immunological mechanisms are playing a role in the development of
diabetes in the mice , since the signs of diabetes appear at the time antibody
production is building strongly and after the virus has been largely removed
from the circulation. Additional studies must be done to determine what is
taking place to cause the diabetic signs to appear at this time.
The staining for insulin in the tissues worked very well and seemed to
be specific. However, it did not appear sensitive enough to stain insulin in the
plasma that was contained in the tissue sections. It is possible that fixation
with formalin masked the insulin antigens in the plasma but left sufficient
insulin antigens unmasked in j3-cells to enable good staining to take place in
the cells.
At the time this investigation began, it was not possible to purchase
antiserum directed against EMC virus. Since it was necessary to have a good
primary antibody specific for EMC virus in order to discern those tissues
producing virus antigen during the infection, production of antiserum in
animals other than mice was necessary. Guinea pigs were the first choice,
since Tyrrell (1 07) stated that they produced better antibody to rhinoviruses
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(which are in the same family, picornavirus, as EMC virus) in general than did
rabbits . It was thus reasoned that less antigen would be needed to illicit a
good antibody response if guinea pigs were used . However, the results of
attempts to produce antiserum that would cause specific staining in the
immunohistochemical staining procedure were disappointing.

Two of the

inoculated guinea pigs died of unknown reasons and a postmortem
examination (gross necropsy observations and histopathology) did not reveal
the cause of death. Both animals appeared healthy the day before they were
found dead in their cages. Other guinea pigs inoculated with virus produced
neutralizing antibody in moderately high titers, but no specific staining could
be obtained on the tissue sections.
It is possible that lgM antibody was responsible for much of the
neutralization of the virus. Any virus-specific lgM antibody would probably
interfere with the immunohistochemical staining because the secondary
antibody used was specific for guinea pig lgG . Thus, if lgM antibody covered
some, or all, of the viral antigens in the tissues. there would be fewer sites at
which lgG antibody could attach . The secondary antibody necessary for
specific staining would then have few , if any, sites for attachment.
Results of attempts to produce anti-EMC virus antiserum in the rabbit
were more promising in that higher neutralizing antibody titers were obtained
in this species. However, when these antiserum samples were used as the
primary antibody in the immunohistochemical staining technique , a similar
lack of specific staining was seen . It was decided to separate the lgG from the
lgM of the rabbit serum, since it was easier to obtain large volumes of the
rabbit serum and since this serum also had higher titers of neutralizing
antibody than did the guinea pig serum samples.

Once the lgG was

separated, it was found to react specifically in the immunohistochemical
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staining technique. The lgM must have been reacting with the virus antigens
in the tissues to such an extent that lgG was not able to bind to these antigens.
The secondary antibody was thus unable to attach and begin the network
necessary to provide a visible marker at the site of virus antigen production.
It was an unexpected finding that spleen tissue was the only tissue
which stained in a specific manner when anti-EMC-0 virus antiserum was
used. Infectious virus was isolated at respectable titers from all of the other
tissues studied . In fact, infectious virus was recovered from pancreatic tissue
at higher titers (on a per gram of tissue basis) than found in spleen tissue,
except at 23 and 35 hr p.i. (Fig . V-3). Yoon et al. (15) had shown the presence
of viral antigen in the islets of Langerhans of infected mice by direct
fluorescence assay. They used mouse anti-EMC virus antibody labeled with
fluorescein isothiocyanate (FITC) and frozen sections of mouse pancreas. No
one has described staining sections other than pancreas tissue, and that
tissue has only been stained by FITC-Iabeled anti-EMC virus antisera.
The reasons for failure to specifically stain the EMC-0 virus antigen in
all tissues are not known. However, it is known that fixation of the tissue can
mask the antigens within the tissue. The antigens masked by formalin-fixation
can often be partially rejuvenated by brief protease treatment (1 08, 109).
Treatment of tissue sections with trypsin did seem to restore specific
staining to lung, liver, kidney, heart, and thymus tissues. However, pancreas
tissue was always dislodged from the slide during the trypsin treatments.
Lung, liver and heart tissues were dislodged 2 of 5, 2 of 5, and 3 of 5 times ,
respectively, when trypsin treatment was tried on these tissues. Therefore,
trypsin treatment is not recommended when one is attempting to stain several
different tissues at several time periods in order to obtain comparative results.
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Immunohistochemical staining for IFN-13 in the tissue sections seemed
to be specific according to a lack of stain when negative control serum was
used instead of primary antiserum , and according to the direct relationship
between concentration of primary antiserum used and the resulting stain
intensity. However, the staining of the nuclei of certain cells indicated that
some non-specific staining was occurring, since IFN should be produced in
the cytoplasm of the cell. This stain in the nucleus was possibly due to avidin
binding to the nucleus, as had been seen on a much more pronounced scale
when particular batches of distilled water were used to prepare rinse buffers
for the Vectastain® procedure. If the nuclear staining was due to non-specific
avidin binding, such binding should also have occurred when the negative
control serum was used, and this did not happen.
At this time, it is not possible to rule out non-specific staining in the case
of the stain seen over the nuclei of certain cells. On the other hand, a definite
reason for such staining is not known.

The staining seen in tissues from

uninfected mice would also lead one to suspect non-specific staining .
However, it could also indicate that sufficient IFN is locally produced to
accomplish its normal regulatory functions, and the staining is sensitive
enough to detect this low level of IFN.
Comparative staining of both virus-infected and control tissues was
successfully done at only the 125 hr time period. In that comparison between
2 mice , all tissues taken from the infected mouse stained darker than those
from the uninfected mouse.

Tissues from virus-infected mice were also

stained at the 29 hr and the 72 hr time periods. They showed no stronger
staining than those taken at 125 hr p.i., even though the antiviral activity of
circulating IFN taken at the 2 earlier time periods was 300- to 1,000-fold higher
than at 125 hr p.i.
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Staining of tissues from both virus-infected and control mice which
could be directly compared was attained at only 47 hr p.i., when anti-IFN-a
was used .

The tissues from these 2 mice were stained by use of the

Histogen ® immunostaining kit. Pancreas, lung , spleen, and thymus were the
only tissues which specifically stained. Most of the stain occurred in areas
which appeared to be plasma . Smooth muscle cells around large airways of
the lung tissues (both mice) had dark staining cytoplasm . There was no
difference in stain intensity between control and virus-infected mouse tissues.
The negative control serum did not allow staining of any tissue , thus
indicating that the IFN-y staining patterns were specific, though somewhat
unanticipated. Tissues from only 2 time periods were successfully stained
with the anti-IFN-y antiserum .

The differences in intensity were not

overwhelming . Therefore , general conclusions cannot be established without
further work to determine if such differences are consistent through all time
periods .
It is interesting to note that the differences occurred in tissues in which
high concentrations of T-cells would be expected. It is possible that the virus
infection could reduce the overall T-cell population or at least reduce one of
the T-cell sub-species.

Conclusions.

Although the two immunostaining kits examined for

these studies are advertised for use on formalin-fixed, paraffin-embedded
ti ssue sections, other fixatives may be best for some of the antigen/tissue
combinations involved in these studies. In particular, B5 fi xative is better for
most antigens than is formalin, according to a personal communication from
Jonathon N. Schumaker, histologist/technical services manager, Lipshaw
Corp.
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lmmunostaining for EMC-D virus antigen was only successful in tissues
other than spleen if the tissues were treated with trypsin.

The trypsin

uncovered some of the virus antigen. It also completely dislodged some of the
tissue sections from the slides, even though the slides had been treated with
Elmer's glue to gain better adherence.
Insulin was well stained in the islets of Langerhans. The islets were
reduced in size and/or demonstrated a reduced presence of insulin in
pancreas tissue taken from virus-infected mice beginning at 54 hr p.i. This
was somewhat surprising since Yoon et al. (15) had shown infiltration of
leukocytes in the islets of mice inoculated with virus 7 days earlier. No islet
infiltration of leukocytes was seen in the 5 day period of these experiments.
Infectious virus yield was shown to increase in pancreas, spleen,
kidney, liver, lung, and heart beyond the peak of infectious virus seen in the
plasma.

Infectious virus peaked in thymus tissue before it peaked in the

plasma.
Circulating IFN titer began a precipitous decline to undetectable levels
at the time that infected mice began to develop glycosuria. Whether this rapid
decline in IFN titer had a causative relationship to development of glycosuria
or not remains to be determined.
Observations of the relative time of appearance and change in titer of
various measurable signs of infection, resistance, and diabetes development
have been made. It is hoped that these preliminary observations will enable a
more detailed examination of resistance parameters in mouse tissue by
immunohistochemical methods.

The more detailed examination should

provide some evidence to determine why some mice infected with EMC-D
virus become diabetic while others recover fully from the virus infection.
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CHAPTER VI
SPECIAL OBSERVATIONS CONCERNING
EMC-D VIRUS-INDUCED
DIABETES IN MICE
Three significant observations were made during the outlined EMC-D
virus-induced diabetes research for this dissertation which may appropriately
be described separately from the remainder of the research .

These

observations are outlined in the following sections.

Glucose Excretion in the Saliva of EMC·D-Infected Mice.
Introduction. While attempting to get "obstinate" mice to provide urine samples
for glucose tests, it was observed that they were more likely to urinate when
excited than when placid. The observation was also made that mice were
prone to urinate while biting . In attempts to excite the mice that were not
excreting urine, Clinistix® test strips were provided as a "chew stick" for mice
to bite. On the occasions when mice with glycosuria would bite the stick in a
way that transferred saliva to the indicator pad , a typical glucose reaction
would occur. This observation was pursued and the results are described as
follows.

Materials and methods. Clinistix® or Diastix® test strips and SJUJ mice
were described in the materials and methods section of Chapter Ill.

Results and discussion. Both EMC-D virus infected and control mice
were tested for this reaction .

Diastix® test strips were used to obtain

quantitative glucose readings. Results of the tests are shown in Table VI-I.
Saliva testing was usually positive for glucose when glycosuria was
present. Only one test of saliva was negative when glycosuria was 2:2,000
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TABLE

VI-I. COMPARISON OF GLUCOSE IN SALIVA AND URINE
BY CLINISTix® OR DIASTix® TESTS.

Group

No. mice

No . tests

No. positive

Not infected

26

35

0

Infected, no glycosuria

13a

15

0

52

so··

Infected, with glycosuria 26a

a One mouse tested through day 5 was negative for both saliva and urine
glucose , but on day 6 and after, was positive for both . This same mouse is
included in both counts.
•• P<0.001
mg/ 100 mi. The other negative saliva test occurred on a day when the mouse
provided no urine for testing. The day previous, the urine test on that mouse
was 500 mg/1 00 ml and 3 days after the negative saliva test, his urine was
negative for glucose.
Diastix ® readings were usually lower when saliva was tested as
compared to urine from the same mouse. When the urine reading was

~2. 000

mg/ 100 ml the saliva reading would often match the urine reading . Control
mice and infected mice without glycosuria were always negative for glucose in
the saliva.
The mechanism of glucose secretion in the saliva is not known.

It is

possible that other body secretions also contain glucose when plasma
glucose levels are high, but this has not been studied.

Conclusions.

Mice with high plasma glucose, sufficient to cause

glycosuria, also secrete glucose in the saliva.

Normal mice did not have

measurable glucose in their saliva.

Effect on Diabetogenicity of EMC-D Virus by the Cell Type
Used for Virus Propagation . Introduction .

As noted in Chapter IV,
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partially purified EMC-0 virus was found to have the same diabetogenic
properties in mice as crude EMC-D virus pools. An experiment was carried
out to confirm the observation of Giron et al. (14) that a single passage of
EMC-0 virus in BHK-21 cells eliminated its diabetogenic properties.

In

contrast to the observation of Giron and his associates, it was found that the
EMC-D virus passaged one time in BHK-21 cells was equally diabetogenic in
SJUJ male mice as the EMC-0 virus passaged in L-cells. This experiment is
described in this section.
Materials and methods. A crude virus pool, prepared by passage of
EMC-0 virus a single time in L-cells , was diluted to provide 5 x 10 pfu , 5 x 102
pfu , or 5 x 103 pfu of virus/mouse when 0.1 ml was injected ip. A crude virus
pool prepared by passage of the same EMC-0 virus a single time in BHK-21
cells was diluted to provide 4 x 104 pfu of virus/mouse when 0.1 ml was
injected ip.

Five mice were injected with each concentration of virus and 4

mice were injected with 0.1 ml of diluent as controls. All mice were male SJUJ
mice. Titration of both virus pools was done in L-cells as outlined in Chapter
Ill. Giron et al. (14) also plaque titered their virus pools in L-cells. Their singlepassage virus in BHK-21 cells was used in mice at approximately 1.2 x 104
pfu/mouse.
The mice were monitored for glycosuria as explained in Chapter Ill;
however, the duration of the experiment was extended to 64 days. At 64 days,
remaining mice were sacrificed and plasma was tested for glucose and
neutralizing antibody titers as outlined in Chapter Ill.
Results and discussion. Results of the experiment are shown in Table
Vl-11. Obviously, the virus passaged once in BHK-21 cells was effective as a
diabetogenic agent, with 100% of the mice developing diabetes. The earlier
glycosuria seen in mice given BHK-21 passaged virus was probably due to
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TABLE VI-II. EFFECT OF CELL PASSAGE ON THE DIABETOGENICITY
OF EMC-D VIRUS IN MALE SJUJ MICE.
Virus

Cell

cone.

passage

Qll£QQsuriaa___
Pos./total

First day

(pfu/

all samples

mouse)

were eositive

5x10

L

5x102

L

5x103

L

4x104

BHK-21

5/5

0

[2all 24 QQS! Vir!JS iOQQIJia!iQD
Neutral.
Plasma gluQQS!l
Pos.bftotal Titer: antibody
titerd

6

1/4

~3 38

148

5/5

8

4/5

~6 01

229

5/5

6

1/1

~8 00

70

4

4/4

~7 85

125

0/4

128

<10

5/5

0/4

a Determined by Clinistix® or Diastix®, after Clinistix® was positive.
b ~3 S.D. above the mean plasma glucose cone. of control mice. The same
mice were also glycosuric.
c Mean of all sampled mice (mg/1 00 ml) .
d

Mean of all sampled mice (units/0.1 ml) .

the higher dosage of virus given . The day of first appearance of glycosuria
was dosage dependent in the titration of L-cell passaged virus also.
Giron's group did use a different strain of mouse (ICR Swiss) than was
used in these experiments. They also used a different method, a combination
of plasma glucose levels and glucose tolerance tests, to determine which mice
were considered diabetic or normal. Neither of these differences would seem
to account for the dramatic difference of results seen (0% diabetes with Giron's
group as opposed to 100% diabetes in this study).

The reasons for this

difference are not known.

Conclusions. Passage of EMC-D virus in L- or BHK-2 1 cells did not
affect its diabetogenicity. This observation is in contrast to a report by Giron et
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al. (14). Results of this study indicate that the diabetogenic properties of EMCD virus are reasonably stable upon cell passage.
Correlation of Spontaneous Recovery of Mice from EMC-D
Virus-Induced Diabetes with Reduced Polydipsia and Polyphagia .
Introduction. It had previously been noted (Chapter Ill) that most mice with

EMC-D virus-induced glycosuria developed very wet bedding within a day
after glycosuria was evident. Some mice had been observed to have normal
bedding, with no noticeable sticky wetness present, even though they had
high glycosuria. Mice with normal bedding, whether they had glycosuria or
not, did not utilize as much water or food as the mice with continuously wet
bedding . It was decided to measure the water and food intake of the mice at
different intervals in the experiment to determine if a relationship existed
between severity of diabetes and food or water consumption .
Materials and methods. The water bottle of each individually housed

mou se was weighed each day from days 36 through 40 and again from days
57 through 60 to determine individual water consumption . Food remaining in
the feeding trays of cage lids was weighed on each of the above days to
determine food consumption. Individual mouse weights were recorded on the '
same days. The ratio of mean mouse weight per gram of food utilized or per
gram of water utilized was calculated for each time period. The data for the
time periods were also combined and the above ratios calculated for the
combined data.
Results and discussion. When results of ratios of individual mouse

weights/weight of food or water consumed were sorted in an ascending order,
particular groupings of mice were observed. Those with strong glycosuria,
and wet bedding, at the end of the experiment were grouped as low numbers
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(high food or water intake). Those mice with normal bedding but which had
experienced high glycosuria at some time in the experiment were grouped as
sign ificantly higher numbers. Mean values and standard deviations of the
ratios for each group are listed in Table Vl-111. There was an obvious difference in the data obtained from control mice and mice with wet, sticky bedding .
TABLE VI-lli. RATIO OF MOUSE WEIGHT TO DAILY FOOD OR WATER CONSUMPTION.
Group

MQIJS!l Y:ll t:!Jj Qf fQQQ
Late Combined

Earl~

Diabetic

2.9··±0 .5 2.8 .. ±0.6 2.9 .. ±0 .5

MQIJS!l Y:ll l'i:JJ. Qf wale[
Late Combined

Earl~

0.5..±0.1 0.6 ..±0.2 0.6.. ±0 .1

Curing or cured

5.8±0.6

6.4±0.7

6.1±0.7

2.6±0.9

3.1±1.0

2.7±0.9

Controls

6.5±0.2

6.9±0.2

6.7±0.1

2.9±0.2

4.4±0.6

3 .4±0.4

•• P <0.01, when compared to Curing or cured group.

Two ranges of data were observed for infected mice.

1)

A relatively

continuous range of values from mice with high glycosuria at the end of the
experiment. These values ranged from 2.0 to 3.7 for weight/food consumption
ratio . The ratios for we ight/water consumed ranged from 0.4 to 0.9. 2) A
range of values for mice that were able to control tendencies toward
polyphagia and polydipsia. These mice had recovered, or were in the process
of recovery , from glycosuria. Extremes for this range were 5.2 to 7.2 for food
con sumption and 1.4 to 4.0 for water intake. This range of ratios overlapped
that of the control, uninfected mice, which had extremes of 6.3 to 7.2 for food
and 2.7 to 5.3 for water consumption.

Conclusions. Some of the mice induced to a diabetic state by EMC-D
viru s infection were able to control the polydipsia and polyphagia common to
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diabetes.
diabetes.

These mice recovered spontaneously from the virus-induced
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TABLE A-1. TITRATION OF CRUDE vs PURIFIED EMC-0 VIRUS POOLS.
STANDARD DEVIATIONS FOR PLASMA GLUCOSE AND NEUTRALIZING ANTIBODY.
Titer of virus
inoculum
(pfu/mouse)

Data from mice
sacrificed on
(day)

Plasma glucosea

!Meao +SQl
Crude

Neutralizing antibodyb

!llllatl + s !:l l

Purified

Crude

Purified

4

X

103

9
21
Combined

518 .. ±165
182±20
406 •• ±211

541 .. ±180
308.±180
463 •• ±208

704±466
1120±1213

556±393
1313±1036

4

X

104

9
21
Combined

593 •• ±167
371±288
542 •• ±210

517 •• ±120
459 •• ±182
499 •• ± 136

597±283
2933±462

443±309
1651±701

4

X

105

9
21
Combined

567 •• ±95
512 •• ±255
551 •• ±148

498 •• ±167
392±357
473 •• ±2 11

354±185
3203±1730

482±209
1731±941

9
21
Combined

358 •• ±125
170±28
287".±136

466 •• ±106
161±25
269 •• ±162

458±248
1613±1381

627±508
1878±1284

4 x 105 female

9
21
Combined

174±37
166±26
171±33

a mg/100 ml (±S.D.).
b Units/0.1 ml of plasma. Statistics were not run on this data.
• P<0.05;

•• P<0.01; compared to controls.

0
0
0
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